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ABSTRACT
NOVEL APPROACHES TOWARDS IMPROVED PURITY IN HIGH YIELD
TRANSCRIPTION REACTIONS
MAY 2021
ELVAN CAVAÇ, B.A., ST. OLAF COLLEGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Craig T. Martin
High yields of RNA (e.g., mRNA, gRNA, lncRNA) are routinely prepared
following a two-step approach: high yield in vitro transcription using T7 RNA polymerase,
followed by extensive purification using gel or chromatic methods. In high yield
transcription reactions, as RNA accumulates in solution, T7 RNA polymerase rebinds and
extends the encoded RNA (using the RNA as a template), resulting in a product pool
contaminated with longer than desired, (partially) double stranded impurities. Current
purification methods often fail to fully eliminate these impurities which, if present in
therapeutics, can stimulate the innate immune response with potentially fatal
consequences. This study establishes novel in vitro transcription and purification
technologies for high yield synthesis and purification of only encoded RNA.
First, we demonstrate a simple and economical in vitro transcription method carried
out under high salt with partially single stranded promoter DNA (pss[-5]). This inhibits all
non-promoter specific activity, including RNA self-primed extension, and the system
exclusively generates high yields of encoded RNA. Second, we establish a novel in vitro
transcription system where promoter DNA and T7 RNA polymerase are co-tethered in
proximity on beads to drive promoter binding and initiation, and high salt eliminates all
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RNA product rebinding. The system is robust and reusable up to at least three times
generating more yield of encoded RNA than conventional methods. Third, we develop
novel affinity purification methods for in vitro transcribed RNA. Immobilized capture
DNA selectively purifies only the desired RNA from a heterogeneous pool of products. In
a novel approach, we improve binding capacity by increasing the binding sites per DNA
oligo bound on beads using rolling circle amplification. We also introduce a universal
capture DNA purification system that can capture any sequence of RNA without changing
initial system components. Finally, we present a novel RNA microfactory that establishes
the first flow in vitro transcription technology. In this new approach, encoded RNA is
generated and continuously removed from the reaction chamber. This prevents primer
extension and thus dramatically reduces double stranded impurities. By dramatically
reducing extension of the desired RNA product, we achieve a high yield of relatively
monodisperse, correct RNA products.

x

TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS ...................................................................................................v
ABSTRACT....................................................................................................................... ix
LIST OF TABLES .............................................................................................................xv
LIST OF FIGURES ......................................................................................................... xvi
1. INTRODUCTION .................................................................................................19
RNA therapeutics: a revolutionary class of drug transforming the field
of medicine.......................................................................................................19
The rise of mRNA therapeutics during the COVID-19 pandemic ..................20
Generating large quantities of pure RNA for therapies ...................................21
T7 RNA polymerase for in vitro transcription of RNA ...................................22
Origin of transcription byproducts by T7 RNA polymerase ...........................22
The problem with long, double stranded impurities in RNA
therapeutics applications ..................................................................................23
Need for novel transcription and purification methods to generate high
yields of pure RNA ..........................................................................................24
Objective of this study .....................................................................................25
2. IN VITRO TRANSCRIPTION USING TIGHT BINDING PROMOTER AT
HIGH SALT PREVENTS CIS PRIMED EXTENSION ACTIVITY, WHICH
NEARLY ELIMINATES LONGER, DOUBLE STRANDED IMPURITIES .....27
2.1 INTRODUCTION ...........................................................................................27
2.2 MATERIALS AND METHODS.....................................................................28
2.2.1
Reagents ..........................................................................................28
2.2.2
T7 RNA polymerase ........................................................................29
2.2.3
Transcription reactions ....................................................................29
2.2.4
Gel electrophoretic analyses ............................................................29
2.3 RESULTS ........................................................................................................29
2.3.1
Selection of a Promoter DNA For Exclusive PromoterDriven Transcription at High Salt ...................................................30
2.3.2
Exclusively promoter-driven transcription at high salt using
pss[-5] promoter ..............................................................................31

xi

2.3.3
2.3.4

Yield of encoded RNA is not affected by high salt using
pss[-5] promoter ..............................................................................33
Generality of the solution ................................................................35

2.4 DISCUSSION ..................................................................................................37
2.4.1
Using pss[-5] DNA drives promoter driven transcription
over cis primed extension ................................................................37
2.4.2
Transcription using pss[-5] template DNA is salt resistant .............38
2.4.3
Generality of the solution ................................................................39
2.4.4
Some polymerase falls of in the transition to elongation due
to tight promoter binding .................................................................39
2.5 SUMMARY .....................................................................................................40
3. HIGH SALT TRANSCRIPTION WITH DNA AND T7 RNA POLYMERASE
CO-TETHERED TO BEADS GENERATES INCREASED YIELDS OF
HIGHLY PURE RNA............................................................................................42
3.1 INTRODUCTION ...........................................................................................42
3.2 MATERIALS AND METHODS.....................................................................44
3.2.1
Reagents ..........................................................................................44
3.2.2
T7 RNA polymerase ........................................................................45
3.2.3
Strep-T7 RNA polymerase ..............................................................45
3.2.4
Untethered transcription reactions...................................................45
3.2.5
Tethered transcription reactions ......................................................45
3.2.6
Reuse of the tethered complex for transcription reactions ..............46
3.2.7
Gel electrophoretic analyses ............................................................46
3.3 RESULTS ........................................................................................................47
3.3.1.
Design of a Tethered in vitro Transcription System .......................47
3.3.2.
Tethered system favors promoter-directed transcription at
high salt ...........................................................................................49
3.3.3.
Synthesis of encoded RNA is not impaired by tethering ................51
3.3.4.
Generality of the system ..................................................................53
3.3.5.
Biotinylated DNA and Strep-T7 RNA polymerase bind at
nearby tetrameric sites .....................................................................54
3.3.6.
Use of tight binding pss[-5] and added salt allows in
tethered transcription .......................................................................57
3.3.7.
The system is stable and reusable....................................................59
3.4 DISCUSSION ..................................................................................................61
3.4.1
Tethering plus salt leads to improved transcription purity
and yield. .........................................................................................62
3.4.2
Bead co-localization renders transcription resistant to salt .............63

xii

3.4.3
3.4.4

Generality of the system ..................................................................63
Stability of the system .....................................................................64

3.5 SUMMARY .....................................................................................................65
4. NOVEL METHODS FOR THE AFFINITY PURIFICATION OF ENCODED
RNA .......................................................................................................................68
4.1 INTRODUCTION ...........................................................................................68
4.2 MATERIALS AND METHODS.....................................................................69
4.2.1.
Reagents ..........................................................................................69
4.2.2.
T7 RNA polymerase ........................................................................70
4.2.3.
Transcription reactions ....................................................................70
4.2.4.
DNAse I reactions ...........................................................................70
4.2.5.
RNA self-primed extension reactions .............................................70
4.2.6.
Gel electrophoretic analyses ............................................................71
4.2.7.
Bead binding and elution experiments ............................................71
4.2.8.
Other reagents..................................................................................71
4.3 RESULTS ........................................................................................................71
4.3.1.
Capture purification post synthesis .................................................71
4.3.2.
Capture during synthesis .................................................................73
4.3.3.
Generality of the approaches ...........................................................75
4.3.4.
Increasing the capacity of the system ..............................................77
4.3.5.
Rolling Circle Amplification as a tool to improve binding
sites per oligo bound on beads ........................................................80
4.3.6.
Rolling circle amplification of capture DNA sequence in
solution ............................................................................................81
4.3.7.
Binding the amplified capture DNA to streptavidin beads .............83
4.3.8.
Binding to dT(25) beads.....................................................................84
4.3.9.
Universal Purification System .........................................................90
4.3.10. Free 3’ RNA. ...................................................................................92
4.3.11. Blunt 3’ RNA. .................................................................................95
4.4 DISCUSSION ..................................................................................................96
4.4.1.
Capture DNA immobilized on magnetic beads ...............................97
4.4.2.
Increasing the binding sites DNA oligo immobilized on
magnetic beads ................................................................................98
4.4.3.
A universal reagent for the affinity tag purification of
desired RNA ....................................................................................99
4.5 SUMMARY ...................................................................................................100

xiii

5. A NOVEL MICROFLUIDIC RNA MICROFACTORY GENERATES HIGH
YIELD RNA WITH SUPERIOR PURITY .........................................................103
5.1 INTRODUCTION .........................................................................................103
5.2 MATERIALS AND METHODS...................................................................105
5.2.1
Reagents ........................................................................................105
5.2.2
T7 RNA polymerase ......................................................................106
5.2.3
Strep-T7 RNA polymerase ............................................................106
5.2.4
Manufacturing of the Microfluidic Device Mold ..........................106
5.2.5
Manufacturing of the PDMS-Glass Microfluidic Device .............106
5.2.6
Batch transcription reactions .........................................................107
5.2.7
Preparation of bead co-tethered system before packing ................107
5.2.8
Flow transcription reactions ..........................................................108
5.2.9
Gel electrophoretic analyses ..........................................................108
5.3 RESULTS ......................................................................................................108
5.3.1.
5.3.2.
5.3.3.
5.3.4.
5.3.5.
5.3.6.
5.3.7.

Design of a microfluidic in vitro transcription device ..................109
Fabrication of the microfluidic in vitro transcription device ........111
Packing the microfluidic device with bead-tethered
transcription complex ....................................................................112
Microfluidic in vitro transcription using fully double
stranded promoter DNA generates encoded RNA ........................113
Tight binding promoter DNA [pss-5] retains tethered system
components under flow conditions................................................115
Decreased flow rate allows synthesis of primer-extended
RNA...............................................................................................117
Comparison of batch and flow synthesis .......................................119

5.4 DISCUSSION ................................................................................................120
5.4.1
A novel microfluidic in vitro transcription device ........................121
5.4.2
Strengthening promoter contacts using pss[-5] helps retain
template DNA on beads, allows for longer transcription runs ......122
5.4.3
Increased flow rate prevents RNA accumulation near T7
RNA polymerase eliminating its cis primed extension
activity ...........................................................................................123
5.4.4
Device produces comparable RNA yield to high yield batch
in vitro transcription reactions .......................................................125
5.5 SUMMARY ...................................................................................................126
6. CONCLUSIONS & FUTURE DIRECTION ......................................................128
BIBLIOGRAPHY ............................................................................................................142

xiv

LIST OF TABLES
Table

Page

Table A1.

DNA sequences used in Chapter 2 ............................................... 41

Table A2.

DNA sequences and constructs used in Chapter 3 ....................... 67

Table A3.

DNA and RNA sequences and constructs used in Chapter 4 ..... 102

Table A4.

DNA sequences and constructs used in Chapter 5 ..................... 127

xv

LIST OF FIGURES
Figure

Page

Figure 2.2. Using pss[-5] promoter in high salt transcription dramatically
reduces primer extension .............................................................................. 32
Figure 2.3. Transcription is salt resistant using pss[-5] ............................................ 34
Figure 2.4. Generality of solution on other RNA ..................................................... 36
Figure 3.1. Crosslinked transcription complex ......................................................... 48
Figure 3.2. Effect of Strep Tag® II and nontemplate biotinylation on high
yield solution transcription of RNA-24 ........................................................ 49
Figure 3.3. Tethered, high salt transcription dramatically reduces primer
extension ....................................................................................................... 51
Figure 3.4. Transcription by tethered complexes is salt resistant. ............................ 52
Figure 3.5. Improvements are independent of RNA length ...................................... 53
Figure 3.6. Effect of Strep Tag® II and nontemplate biotinylation on high
yield tethered transcription of RNA-24 ........................................................ 54
Figure 3.7. Challenging the Tethered System with Untethered Promoter DNA ...... 55
Figure 3.8. Saturating the free tethered enzyme with modified promoter DNA ...... 56
Figure 3.9. pss[-5] promoter DNA at high salt generates more yield when used
in tethered system ......................................................................................... 58
Figure 4.1. Design of an affinity capture RNA purification method ........................ 69
Figure 4.2. Purification of RNA-24 post transcription using capture DNA
immobilized streptavidin bead ...................................................................... 73
Figure 4.3. Capture & purification of RNA-24 during transcription using
capture DNA-24 beads .................................................................................. 74
Figure 4.4. Capture DNA Purification of RNA-34Alt .............................................. 76
Figure 4.5. Capture DNA binding capacity of Strep-Tactin®XT beads .................. 78

xvi

Figure 4.6. Synthetic RNA-24 binding and elution on high capacity StrepTactin®XT beads .......................................................................................... 79
Figure 4.7. Design of a novel method to improve capacity per oligo bound on
beads ............................................................................................................. 81
Figure 4.8. Scheme of Rolling Circle Amplification of Capture DNA sequence
and subsequent immobilization on streptavidin magnetic beads .................. 82
Figure 4.9. Circularization and rolling Circle Amplification of Capture DNA,
followed by its subsequent binding to RNA-24............................................ 84
Figure 4.10. Scheme of Rolling Circle Amplification of Capture DNA
sequence and subsequent immobilization on dT(25) magnetic beads ............. 85
Figure 4.12. Controlling rolling circle amplified DNA length by increasing
ddNTP/dNTP ratios and their analysis with restriction digest using Dra
I ..................................................................................................................... 87
Figure 4.13. Rolling circle amplified DNA reactions on covalently bead
immobilized T(25) DNA primer with increasing ddNTP/dNTP ratios
and their analysis using restriction digest Dra I ............................................ 89
Figure 4.14. Binding of synthetic RNA-24 on rolling circle amplified dT(25)
magnetic beads .............................................................................................. 90
Figure 4.15. A universal capture DNA purification system ..................................... 91
Figure 4.16. Universal capture purification of RNA-24 using method
introduced in Figure 15A .............................................................................. 94
Figure 4.17. Transcription of RNA-24 under high yield conditions in the
absence and presence of dual capture DNA 1 and 2 and their
consequent DNAse I treatment ..................................................................... 96
Figure 5.3.1. Design of a microfluidic transcription device .................................. 110
Figure 5.3.2. Microfluidic device fabrication ......................................................... 112
Figure 5.3.3. Packing the microfluidic device with bead-tethered transcription
complex ....................................................................................................... 113
Figure 5.3.4. Microfluidic in vitro transcription using fully double stranded
promoter DNA generates encoded RNA .................................................... 115

xvii

Figure 5.3.5. Continuous RNA production without significant loss in yield
using pss[-5] promoter DNA ...................................................................... 117
Figure 5.3.6. Increasing flow rate reduces RNA accumulation in reaction
chamber, preventing RNA 3’ self-extension .............................................. 118

xviii

CHAPTER 1
INTRODUCTION
RNA therapeutics: a revolutionary class of drug transforming the field of medicine
Traditional medicine uses small molecules or proteins as drugs that work by binding a
target protein(1, 2). The patient usually has to take a cocktail of these drugs, most often very
routinely, to exert the desired pharmacological effect. Each drug gets developed for a specific
protein-small molecule or protein-protein interaction, and research findings from one treatment
can often not be applied for another disease. These drugs also generalize diseases to be the same
way for each patient, disregarding factors that may be unique to each case. In addition, the high
dose administration requirement is simply daunting, and expensive.
RNA therapies offer a novel class of drugs that have the potential to transform our
understanding of medicine(3, 4). Messenger RNA (mRNA) translates the information from DNA
into functional proteins (i.e. enzymes, growth factors). Therapies using silencing RNAs (siRNA)
or microRNAs (miRNAs) target and bind host mRNA, to stop the translation for damaged proteins
(5–8). Another approach in RNA therapies is to deliver mRNA directly into the cells (9, 10). This
way, mRNA is used as replacement therapies to encode for a missing protein, or as vaccines to
encode for a specific antigen. This is a powerful approach, since once the mRNA delivery platform
is established, you can target any disease just by changing the sequence of the mRNA.
RNA therapeutics have the potential to target many diseases from rare to common and
have the benefit of customization for personalized treatments. Once a treatment is designed for a
patient, dose administration may be significantly lower when compared with traditional drugs.
Some approved RNA therapies in recent years have started generating profit (11–13), and
as a result, RNA therapeutics companies have attracted increased investments and market
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capitalization in the last 5 years. For example, three large mRNA therapeutics companies
(Moderna Therapeutics, CureVac and BioNtech) attracted billions in investment in recent
years. Moderna Therapeutics was valued at ~$7.6 billion in 2018, which was a record for a biotech
IPO (12). Especially in 2020, with the promise of a COVID-19 vaccine, its market valuation went
up to $40 billion. While Moderna has seen one of the most impressive surges, other biotech
companies who work on establishing a COVID-19 vaccine have also seen ballooning in their
market valuation (12). In the light of a new world order, paralyzed under the COVID-19 pandemic,
the fast and efficient promise of mRNA technology has attracted more attention and investments
to bring this powerful technology to the forefront of major medical needs. That is to be said, the
field of RNA therapeutics has finally crossed the bridge from a “future promise” to a working
technology for treating rare to common diseases.
The rise of mRNA therapeutics during the COVID-19 pandemic
On January 11 of 2020, the whole genome sequence of a novel coronavirus (2019-nCoV)
was shared by Chinese researchers. On March 11, the World Health Organization (WHO) declared
COVID-19 a pandemic, warning of its likely (and rapid) spread throughout the world. Yet, even
before this declaration, the possible global health emergency was recognized by many researchers
and biotechnology companies. They responded quickly within their research directions and
capabilities.
Since then, over 130 vaccine candidates have been developed and mRNA-based vaccines
were the frontrunners in the race to a vaccine (14) There are two main reasons for this: speed and
versatility of RNA therapeutics. To be more specific, within only two days of the publication of
the 2019-nCoV sequence, Moderna Therapeutics and the National Institutes of Health (NIH)
infectious disease research teams finalized the sequence of mRNA-1273, an mRNA vaccine, and
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in record turnaround time in medical history, Moderna shipped the vaccine to NIH to start Phase
1 clinical studies on February 24 (within 6 weeks of the sequencing) (15, 16). In addition to their
strength in turnaround time, the versatility of the approach is attractive to establish a long-time
platform, as opposed to a one-time fix. This is due to the fact that viruses change and mutate in
response to drugs, and in traditional vaccines, a novel vaccine would have to be established for
each mutated virus type. For mRNA vaccines and therapies, once the platform is well established,
the system can be applied to a novel virus just by changing the sequence of the mRNA.
The challenge, however, does not end by establishing an effective and safe mRNA vaccine.
Once a vaccine is established, the next challenge is to manufacture billions of doses for the entire
world, which is not a facile task. In fact, many of these companies working on establishing a
vaccine have already made arrangements and collaborations for manufacturing, and even started
manufacturing at some scale (17). Even if the mRNA vaccine sequence may eventually change,
the financial risk was well taken by the government, to get a head start in the manufacturing process
to produce billions of vaccines for the world. However, this was an emergency procedure and
cannot be considered a feasible strategy for high yield production and distribution in the long term.
Generating large quantities of pure RNA for therapies
Now that mRNA vaccines are at the forefront as a relief for the COVID-19 pandemic, there
is a requirement of manufacturing high-quality vaccine for billions. It is essential to produce large
quantities of RNA to be used in these vaccines, but the RNA also needs to be of high fidelity. In
RNA therapeutics applications, in vitro transcription by T7 RNA polymerase is routinely used to
synthesize for messenger RNA (mRNA) applications, for RNA interference studies (RNAi), or for
the generation of guide RNA (gRNA, ≥100 bases) to be used in CRISPR (18–20). It can also be
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used in basic RNA biology research (aptamers, splicing, riboswitches, CRISPR, lncRNA) and for
nanotechnology(3, 12).
T7 RNA polymerase for in vitro transcription of RNA
T7 RNA polymerase is an extensively studied, promoter specific and robust enzyme and
the transcription of RNA in vitro is an established method to produce high yields of RNA of all
sizes (21–25). T7 RNA polymerase binds its consensus promoter sequence with near nanomolar
affinity in vitro (21, 26), initiates transcription at a unique site in the DNA, transitions to stable
elongation, and runs off the end of a linear DNA template to synthesize the encoded RNA(24, 27–
29). In addition to the full-length encoded RNA, T7 RNA polymerase also produces short abortive
RNAs 2-7 nt in length, intermediate RNAs shorter than the encoded length and RNAs longer than
the encoded length (30, 31).
Origin of transcription byproducts by T7 RNA polymerase
The formation of longer products has been reported in the past and different potential
mechanisms for its generation have been proposed. These include templated and non-templated
additions, cis or trans primed extension of RNA or strand jumping (20, 25, 30–32, 34, 36, 57–60,
71–75, 98).
Templated additions have been proposed to occur by product RNA having some selfcomplementarity and extending itself from the 3’ end intra or intermolecularly. Intermolecular
(trans) primed extension would occur by one RNA molecule sitting on another one and extending
the first RNA from its 3’ end using the other RNA sequence as its template(36, 39). Intra (cis)
primed extension occurs by product RNA looping back and sitting on itself, using its own sequence
as the template for extension (31, 47).
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In strand jumping (36), polymerase synthesizes encoded RNA using the template strand,
but then is thought to jump to the nontemplate strand and continue, using the nontemplate strand
as a template. This would result in the production of longer RNA, and if the conditions allow, can
carry out multiple, sequential strand jumps to produce very long products.
Our lab recently used RNA-seq (32) to demonstrate that in high yield transcription
reactions, the most significant contribution to the longer, undesired RNA products is through the
cis self-primed extension mechanism (31). In this mechanism, as high yields of encoded RNA
accumulate in solution, mass action drives the polymerase to rebind the accumulated RNA at its
3’ end and self-extend in a now promoter independent mechanism. The process is heterogeneous
and distributive, leading to a diverse pool of products often abundant in (partially) double stranded
RNAs longer than the encoded length.
The problem with long, double stranded impurities in RNA therapeutics applications
In RNA therapeutics applications, using pure RNA is crucial in its safe administration in
patients. Double stranded RNA is classified as a potent pathogen-associated molecular pattern in
the body. Indeed, it has also been reported that in vitro transcription reactions can invoke the innate
immune response, primarily via the double stranded impurities. Natural sensors like retinoic acid
inducible gene (RIG-I) (48, 49), Toll-like receptor 3 (TLR-3) (50–53), protein melanomadifferentiation-associated antigen 5 (MDA5) (48) may recognize the in vitro transcribed RNA and
double stranded impurities and induce the innate immune response. Double stranded RNA can
also inhibit translation through the activation and upregulation of protein kinase R (PKR) (54) or
cause cellular mRNA degradation by activating the 2’-5’ oligoadenylate synthetase (OAS) enzyme
family (55).
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Need for novel transcription and purification methods to generate high yields of pure
RNA
With the rise of the RNA therapeutics industry in recent years, production of large scale,
high purity mRNA has been a challenge for many researchers and companies. There has been
significant effort in establishing a superior RNA production method or device to generate large
quantities of RNA in a robust yet inexpensive manner (56–59). Especially for in vitro transcription
reactions of long RNAs, constant waste of template DNA has been the most significant cost factor.
Some attempts have been made in recent years to improve in vitro transcription. One such method
to generate RNA focuses on the prevention of cis primed extension activity of polymerase,
resulting in a decrease in the longer double stranded impurities (47).
Another approach, a bioreactor for in vitro batch transcription, has been filed as a patent
by Curevac and Tesla Grohmann (57). In this batch approach, an ellipsoidal vessel, containing a
magnetic bead immobilized template DNA holds a solution with transcription components, such
as NTPs, T7 RNA polymerase and reaction buffer. Template DNA immobilized free floating
magnetic particles are mixed by the moving of a magnet. This follows a batch reaction model,
where repeated batch reactions reuse the same template DNA, saving on its cost. Another
advantage of such a bioreactor, besides reusability of template DNA, is its scalability. However, it
is important to note that this batch mode reaction does not aid in the prevention of longer impurities
or other promoter non-specific activity of RNA polymerase. As a result, yields of the intended
encoded product will often be low and products still need to go through extensive purification
methods to reach desired purity and quality.
Following in vitro transcription, it is common and essential to purify products using ionpair reversed-phase or other high performance liquid chromatography (HPLC) (49–53). It is also
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possible to employ gel purification, but this method does not generally scale well, with good yield.
While gel purification is arduous, time consuming, and impacts yield loss, HPLC purification is
costly and results in a loss of yield as well. In addition, at long RNA lengths, the resolution in these
separations becomes progressively worse, making the purification of the precisely encoded RNA
unattainable. A recently developed method removes dsRNA impurities from the in vitro
transcription pool by their selective binding to cellulose in an ethanol-based buffer (65). However,
the effectiveness of this method is expected to depend on the relative lengths of double stranded
regions and may remove desired RNAs with natively structured regions.
A successful, high yield purification starts with a high-quality transcription reaction that
does not produce an excess amount of shorter and longer byproducts from the get-go. As
previously mentioned, high yield T7 RNA polymerase in vitro transcription often produces longer,
undesired RNA byproducts as a result of the promoter independent cis self-primed extension
activity. Therefore, one must first start by preventing this activity during transcription, in order to
have a product pool high in yield of encoded RNA, so that they can be successfully purified post
transcription in high yields. Furthermore, it is also essential to improve the current purification
methodologies to adapt to the high pace requirement of RNA therapeutics field, and such method
should be sequence selective, for the realization of extreme purity.
Objective of this study
This study establishes novel in vitro transcription and purification approaches for high
yield synthesis and purification of encoded RNA. Three distinct, novel transcription systems and
devices described in chapters 2, 3 and 5 increase encoded RNA yield and purity by preventing cis
primed extension activity of T7 RNA polymerase through various strategies. Chapter 4 sets the
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foundations for a sequence specific affinity purification method for the purification of only
encoded RNA at high yields.
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CHAPTER 2
IN VITRO TRANSCRIPTION USING TIGHT BINDING PROMOTER AT HIGH SALT
PREVENTS CIS PRIMED EXTENSION ACTIVITY, WHICH NEARLY ELIMINATES
LONGER, DOUBLE STRANDED IMPURITIES
INTRODUCTION
T7 RNA polymerase is a promoter specific and robust enzyme used routinely to synthesize
RNA of all sizes (20, 23, 66, 67). In addition to synthesizing encoded RNA at high yields, it also
transcribes short RNAs (2-7 nucleotides) known as “abortives” (20, 37) and products longer than
desired length (31, 39, 41, 47). T7 RNA polymerase has been reported to participate in an array of
non-promoter driven activities including templated and non-templated addition (38), strand
jumping (36) and cis or trans primed extension of product RNA (25, 31, 47, 68). Using RNA-seq
of in vitro transcription products, our lab recently confirmed that a majority of the longer RNAs in
high yield reactions stem from cis self-primed extension activity (31, 32). As high yields of RNA
accumulate in solution, T7 RNA polymerase re-binds the product RNA and extends its 3’ end,
using upstream RNA as its template (31, 32, 68). The process is heterogeneous and distributive
and results in a product pool full of (partially) double stranded, longer than desired length RNAs.
This results in large abundances of RNA incorrect in size, and often structure, complicating
purification for end users.
In RNA therapeutics applications, double stranded RNA (dsRNA) contamination is known
to invoke the innate immune response, and dsRNA is known as a pathogen-associated molecular
pattern in the body (69). Therefore, in vitro transcription is often followed up by extensive
purification steps using gel or chromatographic methods (62, 63). These arduous methods often
result in a loss of overall RNA yield, plus, if the product pool is mostly self-extended, most
abundant product is often not the correct one. Purification methods that focus on the most abundant
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product may be purifying the wrong product. Furthermore, in the generation of long RNA, such
as mRNA, it is not possible to distinguish longer products that are only extended by 40 nt (in a
1800 nt mRNA encoded product), for example, which although may be overlooked, can and will
trigger the innate immune response! Therefore, to accurately prepare the desired, encoded RNA
product, it is necessary to generate correct sequence and length RNA in the transcription reaction
first.
The purpose of this research is to establish a novel in vitro transcription method that inhibits
product RNA rebinding, while fully retaining promoter driven transcription. We use a partially
single stranded promoter DNA (pss[-5]), to favor promoter driven transcription, as this construct
has at least four-fold tighter promoter binding relative to the fully double stranded construct (70).
Strengthening promoter binding favors promoter driven transcription over product RNA
rebinding. To further eliminate RNA rebinding activity in solution, we increase salt concentrations
in solution without destroying promoter binding. This way, we hypothesize to generate only
encoded RNA without the double stranded impurities at high yields.
MATERIALS AND METHODS
2.2.1

Reagents

DNA oligonucleotides used in transcription reactions were purchased from Integrated
DNA Technologies (IDT). Sequences are shown in Table A1. All buffers were prepared and
optimized for their specific use in house. High yield transcription buffer: 30 mM HEPES, 40 mM
magnesium acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8.
Pyrophosphatase (New England Biolabs, M2403L) was added to a final concentration of 10
units/ml in all transcription reactions.
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2.2.2

T7 RNA polymerase

His-tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying
the plasmid pBH161; purified and characterized as previously described (29).
2.2.3

Transcription reactions

All reactions were performed with house optimized and prepared high yield transcription
buffer (as shown in Reagents) in the presence of 0.8 μM of nontemplate and template DNA, 0.8
μM T7 RNA polymerase and 7.5 mM of each NTP in final volume of 20 μl at 37°C for 4 h.
Transcription was stopped by heat denaturation at 95 °C for 5 min.
2.2.4

Gel electrophoretic analyses

Transcription reactions were labeled with [α-32P]ATP (PerkinElmer). All reactions were
analyzed with 20% polyacrylamide, denaturing (7M urea) gel electrophoresis. Gels were imaged
with a GE Typhoon FLA 9500 Phosphorimager. Quantifications of gel lanes were performed using
ImageJ V 1.52s on raw TIF output.
RESULTS
In this research, we use partially single stranded promoter DNA (pss[-5] DNA), where
nontemplate strand is deleted downstream of position -5, to favor promoter binding over RNA
product rebinding during in vitro transcription. T7 RNA polymerase binds this partially single
stranded DNA four times tighter (Kd ≈ 1.1 nM) than the fully double stranded promoter DNA (Kd
≈ 4 nM) (70). The tight binding of the pss[-5] DNA favors promoter-driven transcription over nonpromoter driven activities of polymerase. To further eliminate all RNA rebinding and extension
activity, we increase added salt concentrations to reduce all RNA polymerase interactions while
retaining strong promoter binding. High salt inhibits all nucleic acid enzyme interactions, but
because we are starting with higher affinity, that reduction still allows good and stable promoter
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binding. This way, only high yields of encoded RNA are synthesized, and double stranded
impurities are reduced dramatically.
2.3.1

Selection of a Promoter DNA For Exclusive Promoter-Driven Transcription

at High Salt
In the 23-base pair consensus T7 promoter, duplex recognition element stretches from -17
upstream to -5 downstream position, while the AT rich melting region extends between the
positions -4 and -1 (Figure 2.1A), as previously demonstrated in the two-domain model (71). Our
lab has previously demonstrated that T7 RNA polymerase binds the fully double stranded promoter
(herein will be called DS) tightly with a Kd of ≈ 4 nM (Figure 2.1B) (70). A partially singe stranded
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Figure 2.1. Scheme of consensus promoter sequence and polymerase binding domains. A.
Consensus promoter DNA sequence shown in rectangular, and specific duplex recognition
element (-17 to -5) and AT-rich melting region (-4 to -1) indicated. B. Promoter DNA sequences
used in this study. DS and pss[+]2 possess, while pss[-5] lacks melting region, resulting in the
higher affinity of pss[-5] for polymerase binding.
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promoter DNA that extends only to +2 position downstream in the nontemplate strand (herein will
be called pss[+2]) has a Kd similar to that of the fully double stranded promoter DNA (20, 72). As
discussed above, this affinity can be strengthened using a partially single stranded promoter DNA
that has no bases downstream of position -5 in the nontemplate strand (see pss[-5] in Figure 2.1B).
While promoter binding affinities differ significantly between these constructs, transcription of the
encoded product proceeds similarly on DS, pss[+2] or pss[-5] promoter DNA constructs (29).
2.3.2

Exclusively promoter-driven transcription at high salt using pss[-5] promoter

In the results shown in Figure 2.2, we compare high yield transcription reactions using
three different promoters: DS, pss[+2] and pss[-5] under increasing concentrations of added NaCl.
The template DNA in all reactions encodes for RNA-24, a sequence that is known to substantially
participate in RNA 3’ extension activity (32). At low (no added) salt, fully double stranded (DS)
promoter DNA produces the encoded RNA-24 and extended, double stranded impurities, as
reported previously (32) and observed in Figure 2.2A. With increasing added salt, overall
transcription decreases, with near complete inhibition by 0.3 M added salt. The pss[+2] construct,
single stranded in the transcribed region, but double stranded in the melted region to +2, shows a
product profile similar to that of the fully double stranded (DS) promoter construct under all salt
concentrations, as shown in Figure 2.2A.
In contrast, transcription using the more strongly binding pss[-5] promoter DNA shows a
very different transcription profile. Increased strength of promoter binding is drives initiation to
better compete with primer extension, and even at no added salt, the product profile does shift to
favor the encoded length RNA, as shown in Figure 2.2.
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Figure 2.2. Using pss[-5] promoter in high salt transcription dramatically reduces primer
extension. A) Salt dependence of transcription profiles for DS, pss[+2] and pss[-5] analyzed by
20%, 7M urea denaturing gel electrophoresis, labeled via incorporation of [α-32P] ATP. The final
concentrations of NaCl added to the standard reaction mixture are shown. B) Quantification of
individual gel lanes in 2A.
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Increased promoter binding affinity should also render initiation more resistant to
increasing ionic strength. This is also readily observed in Figure 2.2. Increasing concentrations of
added NaCl up to at least 0.2-0.3 M do not significantly decrease the yield of encoded length 24
base RNA for pss[-5]. In contrast, and as expected, primer extension products decrease
substantially.
Data shown in Figure 2.2 clearly demonstrate that with increasing NaCl concentrations,
the enzymatic activity is being pushed toward exclusively promoter-driven transcription with pss[5], and by 0.3 M added NaCl a very large majority of RNA rebinding activity is inhibited. As a
result, a high yield of only encoded RNA is synthesized, while the double stranded primer
extension impurities are dramatically reduced, including the n+1 product.
2.3.3

Yield of encoded RNA is not affected by high salt using pss[-5] promoter

To further substantiate that using partially single stranded promoter DNA (pss[-5]) during
in vitro transcription renders promoter-directed initiation less sensitive to increased NaCl
concentrations, we repeated the experiments above on another template. This template DNA
encodes for RNA-24Alt, a sequence previously shown to not produce significant 3’ cis-primed
extension (32). Figure 2.3A compares the encoded product yield of RNA-24Alt using pss[+2] and
pss[-5] promoter DNA constructs under increasing NaCl concentrations. On pss[+2] promoter
DNA, transcription initially increases at 0.1 M added NaCl. Although RNA-24Alt is reduced
substantially in RNA-primed self-extension, this side reaction still occurs at a low rate, as
evidenced by sensitive RNA-Seq assays (47), and as represented by a faint smear (in Figure 2.3A,
or a “shoulder” in Figure 2.3B) migrating more slowly than the encoded 24mer at 0 M added NaCl.
The ratio of this product to the encoded 24mer decreases with increasing salt, consistent with the
results presented in Figure 2.1. Since transcription activity is redirected to promoter-driven
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synthesis, the yield of the encoded RNA initially increases accordingly with added salt. Beyond
about 0.1 M added NaCl transcription decreases with increasing salt concentration, more sharply
for the pss[+2]reaction than for the pss[-5] reaction, as expected.
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Figure 2.3. Transcription is salt resistant using pss[-5]. A) Salt dependence of transcription
profiles using pss[+2] and pss[-5] template DNA encoding RNA-24Alt, analyzed as in Figure 2.2.
B) Quantification of individual lanes in 3A.
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The observation that net yield of correct length product begins decreasing at lower
concentrations of NaCl for template 24Alt than for template 24, reflects the large reduction in
primer extension in the former. It is reasonable to conclude that initiation begins to slow (promoter
binding decreases) similarly for both constructs, but in the case of template 24, the net yield of
encoded length product increases initially, as encoded length product is chased less to longer, selfprimed extensions. The concentration of added NaCl that yields maximal full-length product will
likely be a function of RNA sequence and should be determined empirically for different RNAs.
This shows that even RNA sequences that are observed to not substantially participate in
primer extension can have longer impurities that cannot easily be observed in gel analyses. Figure
2.3 further proves that in vitro transcription using pss[-5] promoter DNA at high salt yields very
pure encoded RNA without compromise to yield. In summary, while overall RNA yield is affected
at a small degree, the encoded RNA yield and purity is significantly superior at 0.3 M added NaCl
using pss[-5] promoter DNA during high yield in vitro transcription reaction, when compared with
0 M NaCl using pss[+2] promoter DNA.
2.3.4

Generality of the solution

Different RNA sequences have different 3’ cis self-extension rates. In Figures 2.2 and 2.3
we focused on two RNAs of same size, but with different sequences, RNA-24 and RNA-24alt.
Both showed the expected improvements from transcription with pss[-5] constructs at elevated salt
concentrations. To demonstrate the universality of this system for synthesis of clean RNA of most
any size and sequence, we selected two other RNA that are longer in size and have distinct
sequences from each other. We generated a 34 nt RNA (RNA-34) by taking the RNA-24 sequence
used in Figure 2.2 and inserting 10 bases at position +8. Since RNA-24 and RNA-34 have the
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same 3’ terminal sequences, we expected them to behave similarly in primer extension,
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Figure 2.4. Generality of solution on other RNA. A. Low and high salt transcription profiles for
pss[+2] and pss[-5] DNA encoding for RNA-34 and RNA-40,analyzed as in Figure 2.2.
We also designed a completely different RNA sequence (RNA-40), 40 bases in length, that
participates in 3’ cis extension at a rate much less than RNA-24, but slightly more than does RNA24Alt. Figure 2.4 shows results fully consistent with the results in Figures 2.2 and 2.3. In the
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synthesis of each of RNA-34 and RNA-40, the use of a pss[-5] promoter at 0 M added salt increases
polymerase affinity to promoter DNA over RNA rebinding, resulting in the production of
increased encoded RNA relative to longer impurities. Further increasing the added salt
concentration to 0.4 M NaCl slightly drops the overall yield, but gives high purity of encoded
product, as previously observed in Figures 2.2 and 2.3.
DISCUSSION
In this research, we have developed a novel, high yield in vitro transcription approach that
favors promoter-driven transcription and limits the RNA-rebinding and cis primer extension
activity that leads to dsRNA impurities. Pss[-5] promoter DNA has at least four times higher
binding affinity for T7 RNA polymerase and drives most T7 RNA polymerase activity to
promoter-driven transcription. Increased salt concentrations in solution further inhibit RNA
rebinding activity almost completely, with minimal impact on promoter-driven transcription.
Results show only encoded RNA is produced with significantly improved purity without
significant loss in yield.
2.4.1

Using pss[-5] DNA drives promoter driven transcription over cis primed

extension
As expected, high yield transcription using pss[-5] DNA favors promoter binding over
product RNA rebinding, and results in a complete shift in the transcription profile. Increasing salt
concentrations result in the complete inhibition of enzymatic activity when using DS and pss[+2]
DNA, as shown in Figure 2.2. Using system pss[-5] DNA, high salt further inhibits cis-primed
extension activity of T7 RNA polymerase, while allowing promoter-directed transcription to
continue as before, as shown in Figure 2.2. This results in a near complete elimination of the
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longer, double stranded impurities. Since the longer products would have been converted from
encoded-length RNAs, this also results in an overall increase of the desired RNA yield.
Further inspection of the gel data may reveal deeper understanding of RNA rebinding
behavior. Previous findings had strong evidence that even n+1 products are produced by re-binding
of full length (or shorter) RNA, followed by RNA-templated addition of one (or more) bases (47).
Analysis of the traces and quantification profiles in Figure 2.2A and 2.2B, respectively, for the
pss[-5] promoter lanes reveals tentatively assigned n and n+1 products at 0 M added NaCl. As the
salt concentration increases, the n+1 length product disappears relative to the n length product.
Interestingly, an apparent n length product is a larger fraction of the total at the highest salt
concentrations. It is possible that at low salt concentrations, n products are being chased to longer
lengths, a process which disappears at the highest salt levels.
2.4.2

Transcription using pss[-5] template DNA is salt resistant

In order to characterize the salt resistance of transcription using the pss[-5] promoter DNA,
we used a sequence, RNA-24Alt, previously observed to participate in cis primed extension at a
rate much less than RNA-24. Figure 2.3 shows that while all transcription activity gets inhibited
with increasing added salt for pss [+2], RNA-24Alt yield is retained up to 0.3-0.4 M salt using
pss[-5]. At 0.1 M NaCl, the yield of encoded RNA-24Alt increases using both pss[+2] and pss[-5]
template DNAs. This is due to the fact that at 0 M NaCl, some encoded RNA participates in cis
primed extension activity, but at a much lower rate an in a more heterogeneous manner that results
in dispersed longer length RNA impurities. This observed increase in encoded RNA yield
decreases for pss[+2] with increasing added salt, but is retained using pss[-5] up to 0.3-0.4 M NaCl.
At 0.4 M NaCl, the overall yield starts to drop, as high salt inhibits all enzymatic activity, as
observed in Figure 2.2.
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2.4.3

Generality of the solution

We confirmed our initial hypothesis using templates that encoded for very short RNA.
Since all long RNAs are generated using in vitro transcription using T7 RNA polymerase, or one
of its close relatives, we also tested the solution to encode longer RNA with different sequences.
We demonstrated in Figure 2.4, that using pss[-5], RNA-34 and RNA-40 were generated at higher
purity at 0.4 M added salt concentrations. In transcription reactions where template DNA is
synthetic, it is possible to exchange the nontemplate strand used with the short nontemplate used
in pss[-5] constructs. However, for plasmid DNA or linearized long RNA, since double stranded
template DNA is a given in these scenarios, this solution may not be possible to use in already
double stranded long template DNAs encoding for RNA.
2.4.4

Some polymerase falls of in the transition to elongation due to tight promoter

binding
Pss[-5] DNA favors promoter binding over product RNA rebinding, since this promoter
DNA does not have the AT rich melting region. Polymerase has contacts with the duplex upstream
of position -5 in promoter, whereas downstream of position -4, polymerase only interacts with the
template (72). Using pss[-5], we completely remove the requirement for DNA melting, resulting
in the recovery of a portion of the polymerase binding energy that would have otherwise went to
melting of the AT rich melting region. The observation of increased 12-15 nt intermediate products
while transcribing full length RNA using pss[-5] , as shown in Figures 2.2, 2.3, 2.4, 2.5 suggests
strong binding with the promoter recognition region in promoter DNA may impair (but not
destroy) the transition to elongation. On the contrary, using pss[+]2 or DS DNA, no such
intermediates are observed. A behavior similar to this was previously observed by Martin lab. In
that work, Esposito covalently linked promoter DNA to the polymerase for transcription (73). In
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that work, while initiation was observed to not suffer, as expected, only 25% of the initiated
population proceeded to elongation and follows through to the formation of full-length encoded
RNA. In that work, there was a similar observation of increased 12-15 nt intermediate products
that could be a result of the short covalent linkage used in this earlier system. On contrast, in the
system introduced in this chapter, we see most of the initiated population to proceed to full
elongation and falloff, resulting in high yields of encoded RNA production. Nevertheless, the gel
migration of 12-15 nt intermediate products are nowhere near the encoded RNA length (unlike cis
prime extended RNA products); their separation from the encoded RNA in a purification step
should be relatively straightforward.
SUMMARY
In this research, we demonstrate a novel in vitro transcription method as a solution to the
double stranded impurities observed in high yield transcription reactions. With this system, T7
RNA polymerase activity is driven to be much more promoter specific, and under increased salt
concentrations, all other non-promoter specific activity, including RNA self-primed extension is
inhibited. The system is easy to implement, robust and economical. There is reason to expect the
system to be able to produce longer RNA, since it has demonstrated ability for efficient promoter
clearance. It is important to note that although longer, double stranded impurities are prevented
from being generated using this methodology, system results in short RNA products of 12-15 nt
in size. While these RNAs are easily distinguishable by most RNA products longer than 20 nt in
size, it is important to follow up with gel or chromatic purification post transcription.
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Template Strands

A

DNA sequences used in Chapter 2

Nontemplate
Strands

Table A1.

5’-AATTAATACGACTCACTATAGG-3’

NT+2

5’-AATTAATACGACTCAC-3’

NT-5

5’-AATTAATACGACTCACTATAGGAGGTAGTAGAGGTGAAGATTTA-3’ NT24
24 3’-TTAATTATGCTGAGTGATATCCTCCATCATCTCCACTTCTAAAT-5’

24Alt 3’-TTAATTATGCTGAGTGATATCCTCCATGATGCAGCTGCGTAAAT-5’
34 3’-TTAATTATGCTGAGTGATATCCTCCATGCTGAGCGTGCATCTCCACTTCTAAAT-5’
40

3’-TTAATTATGCTGAGTGATATCCTGTAATTGTTAGAATAGAATGAAATGCGTGGGATAAAA-5’

*Consensus promoter sequence shown between dashed lines
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CHAPTER 3
HIGH SALT TRANSCRIPTION WITH DNA AND T7 RNA POLYMERASE COTETHERED TO BEADS GENERATES INCREASED YIELDS OF HIGHLY PURE RNA
3.1 INTRODUCTION
Our understanding of RNA’s central role in biology continues to expand and be exploited.
Researchers across a wide swath of basic science and applied technologies require high yields of
pure RNA. Solid phase chemical synthesis can, in principle, generate RNAs up to 50-100 nt in
length, but both yield and purity decrease with increasing lengths (74–76). Enzymatic synthesis in
vitro by T7 RNA polymerase is widely used to synthesize high yields of RNA of all lengths for
structural studies, basic RNA biology (splicing, riboswitches, CRISPR, lncRNA), therapeutics
applications (mRNA vaccines and therapies, siRNA, gRNA for CRISPR) and nanotechnology (18,
20, 23, 66).
T7 RNA polymerase binds its consensus promoter sequence with near nanomolar affinity
in vitro (70, 77), initiates transcription at a unique site in the DNA, transitions to stable elongation,
and runs off the end of a linear DNA template to synthesize the encoded RNA (18, 20, 28). It has
long been known that in addition to the full-length encoded RNA, T7 RNA polymerase produces
short abortive RNAs 2-7 nucleotides in length (20, 78) and RNAs longer than the encoded length.
These longer products have been proposed to be generated through templated and non-templated
additions (20, 38–40), cis or trans primed extension of RNA (25, 31, 34, 41–45), or strand jumping
(36). Our lab recently demonstrated that in high yield transcription reactions, the most significant
contribution to the longer, undesired RNA products is through the cis self-primed extension
mechanism (31, 32). As high yields of encoded RNA accumulate in solution, mass action drives
the polymerase to rebind the accumulated RNA at its 3’ end and self-extend via a non-promoter
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dependent mechanism. The process is heterogeneous and distributive, leading to a diverse pool of
products often abundant in (partially) double stranded RNAs longer than the encoded length.
In RNA therapeutics applications, dsRNA contamination from in vitro synthesized RNA
can invoke the innate immune response, as dsRNA is classified as a potent pathogen-associated
molecular pattern in the body. This can happen by way of activating natural sensors like retinoic
acid inducible gene (RIG-I) (48, 49), Toll-like receptor 3 (TLR-3) (50, 52, 53) and protein
melanoma-differentiation-associated antigen 5 (MDA5) (48). It can cause the production of type I
interferon, which can inhibit translation through the activation and upregulation of protein kinase
R (PKR) (54). It can also cause cellular mRNA degradation by activating the 2’-5’ oligoadenylate
synthetase (OAS) enzyme family (55). Therefore, therapeutics researchers must follow up in vitro
T7 RNA polymerase transcription with often very extensive purification methods (60–64). Gel or
chromatic (HPLC) purification methods are time consuming, result in a loss of yield, and are
imprecise, as the encoded product may not always be readily identified. At long RNA lengths, the
resolution in these separations becomes progressively worse, making the purification of the
precisely encoded RNA unattainable. A recently developed method removes dsRNA impurities
from the in vitro transcription pool by their selective binding to cellulose in an ethanol-based buffer
(65). However, the effectiveness of this method is expected to depend on the relative lengths of
double stranded regions and may remove desired RNAs with natively structured regions.
Although researchers have long focused on improving the overall yield of in vitro
transcription reactions, we have confirmed with RNA-Seq that the very conditions of high yield
synthesis often drive the correct product into primer extended, double stranded impurities (32).
This not only impacts the overall purity, but also the yield of the encoded RNA.
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In this research, we present a novel method of in vitro transcription that allows promoterdirected transcription while preventing primer extension activity, thereby dramatically reducing
double stranded impurities. In brief, by increasing salt concentrations in solution, we reduce all
protein-nucleic acid interactions. To selectively restore promoter binding, we tether both T7 RNA
polymerase and promoter DNA to a solid support (beads). This drives their association even at
high salt concentrations. Near elimination of RNA rebinding and extension not only results in a
dramatic reduction in longer, primer-extended products, but also nets a dramatic increase in the
yield of encoded RNA.
3.2 MATERIALS AND METHODS
3.2.1

Reagents

DNA oligonucleotides used in transcription reactions were purchased from Integrated
DNA Technologies (IDT). Sequences with modifications are shown in Table A2. Unless otherwise
noted, all transcription reactions were performed using partially single-stranded DNA constructs
where the nontemplate DNA extends to the +2 position downstream of the promoter sequence
(referred to here as pss[+2]). This promoter DNA construct is known to have the same functionality
as fully double stranded promoter DNA (20, 72) and we have found in these studies that it behaves
identically to fully double stranded DNA with respect to salt. The following buffers were
optimized in house and used where indicated. High yield transcription buffer contained final
concentrations of 30 mM HEPES, 40 mM magnesium acetate, 25 mM potassium glutamate, 0.25
mM EDTA, 0.05% Tween20, pH 7.8, 10 units/ml pyrophosphatase (New England Biolabs). Wash
buffer contained 0.5 M NaCl, 20 mM Tris-HCl (pH 7.5), 1 mM EDTA. Storage buffer contained
30 mM HEPES, 15 mM magnesium acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05%
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Tween20, pH 7.8. Nucleoside triphosphates (New England Biolabs) were added to transcription
reactions at final concentrations of 7.5 mM each.
3.2.2

T7 RNA polymerase

His tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying
the plasmid pBH161; purified and characterized as previously described (29).
3.2.3

Strep-T7 RNA polymerase

ATG start codon, Strep-tag® II sequence (WSHPQFEK) and a linker sequence (GGS) were
(followed by the T7 RNA polymerase gene) inserted between the Nco I and Hind III restriction
sites in the plasmid vector pBAD HisA. Strep tagged T7 RNA polymerase was expressed under
the inducible control of the L(+) arabinose promoter, and further purified using Strep-Tactin®
protein purification resin from IBA technologies.
3.2.4

Untethered transcription reactions

All reactions were performed with high yield transcription buffer in the presence of 0.8 μM
(each) of nontemplate and template DNA, 0.8 μM T7 RNA polymerase and 7.5 mM of each NTP,
in an overall 10 or 20 μL reaction volume at 37 °C for 4 h. Transcription was stopped by heat
denaturation at 95 °C for 5 min.
3.2.5

Tethered transcription reactions

To assemble the promoter complex, equimolar (0.8 µM) concentrations of biotinylated
nontemplate DNA, template DNA and Strep-T7 RNA polymerase were incubated at 4 °C for 30
min. Strep-Tactin®XT (5% slurry) beads were washed with storage buffer three times and then
incubated with the above enzyme-promoter complex at 4 °C overnight to form the tethered
transcription system. Tethered transcription reactions contained the equivalent of 0.13 μL dry
beads per 10 μL reaction (0.26 µL for 20 μL reactions). Before each transcription reaction, the
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tethered transcription system was washed twice with wash buffer and once with storage buffer.
Transcription was initiated by the addition of high yield transcription buffer (containing additional
NaCl where indicated) with 7.5 mM of each NTP, in a final reaction volume of 10 or 20 μL at 37
°C for 4 h. After 4 h, the supernatant was separated from the beads and heat denatured at 95 °C for
5 min.
3.2.6

Reuse of the tethered complex for transcription reactions

For the re-use reactions of Figure 5, transcription was carried out at 37 °C for 2 h. As indicated
below, partially single stranded promoter DNA with a nontemplate strand that extends only to +2
position downstream (pss[+2]) or a partially single stranded promoter DNA with a nontemplate
strand that extends only to -5 position downstream (pss[-5]) were used for Figures 5B and 5C,
respectively. After the first reaction was complete, the supernatant carrying the transcription
products was separated from the beads and processed for gel quantification. The second reaction
was then initiated as above, with the addition of fresh high yield transcription buffer and NTPs and
carried out at 37 °C for 2 h. This process was repeated for a third time.
3.2.7

Gel electrophoretic analyses

All transcription reactions, except the reusability reactions shown in Figure 5, were labeled
with [α-32P]ATP (PerkinElmer). The gel showing reusability reactions in Figure 5 was stained with
SYBR Gold Nucleic Acid Gel Stain (Invitrogen). All reactions were analyzed by 20%
polyacrylamide (19:1 acrylamide:bisacrylamide) denaturing (7M) urea gel electrophoresis. Gels
labeled with radioactivity were dried and then imaged with a GE Typhoon FLA 9500
Phosphoimager. Gels labeled with SYBR Gold stain were imaged directly with a Bio-Rad Gel Doc
Go Imaging System Blue Tray. Quantifications of gel lanes were performed using Fiji (79)
software on raw TIF output.
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3.3 RESULTS
The goal of this study is to eliminate RNA product rebinding and subsequent extension
activities of T7 RNA polymerase, while retaining promoter-directed transcription. Like almost all
protein-nucleic acid interactions, both initial binding of T7 RNA polymerase to its promoter and
rebinding of product RNA are stabilized in part by electrostatic interactions between positively
charged residues on the RNA polymerase surface and the negatively charged phosphate backbone
of the DNA or RNA (22, 24, 80, 81). As a result, increasing salt concentrations should destabilize
both promoter DNA binding and product RNA rebinding. We have previously shown that
covalently crosslinking an engineered cysteine (A94C) in the N-terminal domain of T7 RNA
polymerase to a 3’ thiol-modified template DNA creates a locally high concentration of the
promoter near its binding site, allowing promoter binding, even at high salt (73). Initiation
proceeds well and at least some of these complexes transition to the stable elongation phase (73).
Elongation by T7 RNA polymerase is stabilized by the topological locking of the RNA around the
template DNA in the enzyme active site (28) and elongation has been shown to be resistant to
added salt concentrations up to at least 0.2 M NaCl (81, 82).
By tethering T7 RNA polymerase to its DNA promoter and carrying out transcription at
elevated salt concentrations, we can achieve promoter-initiated transcription while preventing
product RNA rebinding that otherwise would lead to cis primed extension activity. We expect this
approach to reduce substantially the production of longer, double stranded RNA impurities.
3.3.1.

Design of a Tethered in vitro Transcription System

In order to tether the polymerase to the promoter DNA and still allow functional initiation
and substantial transition to elongation, we bound each, independently to Strep-Tactin®XT
magnetic beads, as shown in Figure 3.1. The N-terminal domain of T7 RNA polymerase (together
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with a hairpin loop from the C-terminal domain) forms the promoter binding platform (83, 84) and
many N-terminal fusions of T7 RNA polymerase function well in promoter-directed transcription
(85–87). Thus, we fused the Strep-tag® II peptide (WSHPQFEK), followed by a short and flexible
peptide linker (GGS), to the N-terminus of recombinant T7 RNA polymerase (88). Herein, we will
call this Strep-tagged variant Strep-T7 RNA polymerase. The Strep-tag® II peptide has nanomolar
binding affinity to specifically engineered Strep-Tactin®XT coated magnetic beads (89). We also
used 5’-biotinylated nontemplate DNA to independently bind the promoter DNA to the StrepTactin®XT beads. Biotin is reported to have picomolar binding affinity to Strep-Tactin®XT coated
magnetic beads (89).

Magnetic Bead

Strep Tactin-XT

Nontemplate

Biotin

Te
mp
lat
e

iSp18
Strep Tag II®

Strep-T7RP
Figure 3.1. Crosslinked transcription complex. T7 RNA polymerase containing an N-terminal
Strep-tag® II peptide and duplex DNA labeled with biotin at the 5’ end of the nontemplate
strand are bound to (tetravalent) Strep-Tactin®XT coated magnetic beads.
To confirm that the Strep-tag® II peptide addition at the N-terminus of T7 RNA polymerase
does not affect transcription activity, we performed in vitro transcription reactions using Strep-T7
RNA polymerase and promoter DNA (without a biotin tag) encoding a 24 base RNA (RNA-24)
under high yield transcription conditions. The gel analysis in Figure 3.2 demonstrates identical
transcription profiles using T7 RNA polymerase and Strep-T7 RNA polymerase. This confirms
that the addition of the Strep-tag® II peptide has no adverse effect on the activity of T7 RNA
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polymerase. Similarly, biotinylating the upstream end of the promoter has no effect on promoter
function, as also shown in Figure 3.2. Finally, we tested these constructs for transcription activity
at 0.4 M added NaCl and, as expected for the uncoupled species, observed essentially complete
inhibition of transcription in all constructs.
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Figure 3.2. Effect of Strep Tag® II and nontemplate biotinylation on high yield solution
transcription of RNA-24. A. Denaturing gel analysis (20%, 7M Urea) of high yield transcription
of RNA-24 using the corresponding constructs. B. Quantitative analysis of gel in A.
3.3.2.

Tethered system favors promoter-directed transcription at high salt

Having demonstrated that the DNA and protein modifications do not perturb promoter
binding and transcription, we proceeded to test the co-tethered system for function. Given that at
low salt the dissociation constant for duplex promoter binding by T7 RNA polymerase is ≈4 nM

49

(70) we first pre-incubated the 5’-biotinylated nontemplate strand, template strand encoding a 24
base RNA and Strep-T7 RNA polymerase at final equimolar concentrations, as described in the
Methods section. We then incubated the assembled promoter complex with tetrameric StrepTactin®XT coated magnetic beads to form the tethered in vitro transcription system illustrated in
Figure 3.1.
While elevated salt concentrations weaken both promoter binding and RNA rebinding
activities of T7 RNA polymerase, indirectly tethering the polymerase to the promoter (as
demonstrated in Figure 3.1) should restore promoter binding by increasing the local concentration
of promoter DNA compared to free RNA in solution, as observed previously using a direct
tethering approach (73). To test the hypothesis with our tethered in vitro transcription system, we
performed a comparative analysis of transcription between tethered and untethered systems as a
function of increasing concentrations of added NaCl. In order to see the direct effect on cis primed
extension activity, we selected a template strand that encodes a 24 base RNA (RNA-24) known to
serve effectively in 3’ self-extension (32). The gel analysis presented in Figure 3.3A shows that as
added NaCl concentration is increased from 0 M to 0.4 M in 0.1 M intervals, all transcription
activity decreases for the untethered system, and is negligible at 0.4 M added NaCl. In the tethered
system, promoter binding (and transcription) is relatively resistant to increasing concentrations of
added salt, as expected. The data also confirm that product RNA rebinding to polymerase is
inhibited, as there is a dramatic reduction in the formation of primer extension products. At 0.3 M
added NaCl, most of the primer extension activity is inhibited, leading directly to an increase in
the encoded RNA yield. At 0.4 M added NaCl, the overall yield is decreased somewhat relative to
that at 0.3M, but the purity of the encoded RNA is at its highest (and the concentration of the
encoded RNA is substantially higher than in the untethered control). Overall, the tethered
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transcription system under high salt produces significantly improved purity and increased yield of
the correct length product.
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Figure 3.3. Tethered, high salt transcription dramatically reduces primer extension. A. Salt
dependence of transcription profiles for untethered and tethered complexes analyzed by 20%,
7M urea denaturing gel electrophoresis, labeled via incorporation of [α-32P] ATP. The final
concentrations of NaCl added to the standard reaction mixture are shown. B. Quantification of
individual gel lanes in 3.3A.
3.3.3.

Synthesis of encoded RNA is not impaired by tethering

Not all encoded RNAs participate in 3’ self-extension (32). To confirm that the described
tethering does not have an effect on the fundamental efficiency of promoter-directed transcription,
we repeated the above comparative analysis with a template strand encoding another 24 base RNA
(RNA-24Alt) that is known not to participate substantially in 3’ self-extension (32). For the
untethered system, gel analysis of the products presented in Figure 3.4A (and quantified in 3.4B)
shows an overall loss of yield in RNA transcription with increasing added NaCl concentration, as
expected (more subtly, there is an initial increase in 24 base RNA at 0.1 M added NaCl, which
then decreases to barely detectable levels by 0.4 M added NaCl).
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In contrast, Figures 3.4A and 3.4B show that the tethered system, while also initially
showing an increase in the yield of 24 base RNA with increasing NaCl, continues to transcribe
well up to at least 0.3 M added NaCl, and produces more 24 base RNA at 0.4 M than at 0 M added
NaCl. Close inspection of the gel lanes in Figure 3.4A suggests that the RNA-24Alt sequence is
in fact producing primer extended products at 0 M added NaCl, as evidenced by a broad smear
above the 24 base RNA band that decreases with increasing NaCl. Quantification of the extended
products is shown in gray at 10X magnification in Figure 3.4B to better depict this observation.
Thus, even for this construct, the intensity of the 24 base RNA band underestimates the total RNA
produced. According to the model, inhibition of the primer extension that produces the broad
smear would result in higher net amounts of the initially synthesized 24 base RNA, as observed.
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Figure 3.4. Transcription by tethered complexes is salt resistant. A) Salt dependence of
transcription profiles for untethered and tethered complexes encoding RNA-24Alt, analyzed as
in Figure 3.3. B) Quantification of individual lanes in 3.4A. Extended products shown in gray at
10X magnification.
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3.3.4.

Generality of the system

The results presented in Figures 3.3 and 3.4 use DNAs encoding 24 base RNAs with
different sequences. To further test the generality of this system, we took the RNA-24 template
sequence introduced in Figure 3.3 and inserted 10 bases at position +8 to yield DNA that encodes
a 34 base RNA (RNA-34), as shown in Table A2. Paralleling the experiment of Figure 3.3, we
compare in Figure 3.5 untethered and tethered transcription of RNA-34 at low (0 M) and high salt
(0.4 M) added NaCl concentrations. As predicted by the general model, the tethered in vitro
transcription system produces primarily the encoded 34 base RNA at high salt. This result confirms
that the system can be used for RNA of longer lengths to generate high yields of encoded RNA
while preventing the formation of self-extended longer RNA impurities.
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Figure 3.5. Improvements are independent of RNA length. A) Low and high salt transcription
profiles for tethered and untethered complexes analyzed as in Figure 3.3. B) Gel quantification
of Figure 3.5A.
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3.3.5.

Biotinylated DNA and Strep-T7 RNA polymerase bind at nearby tetrameric

sites
To encourage both enzyme and DNA to attach to the same Strep-Tactin®XT tetramer in
the above experiments, we preincubated (at low salt) Strep-T7 RNA polymerase and biotinylated
promoter DNA before adding the Strep-Tactin®XT magnetic beads. Following assembly, a high
salt wash was used to remove components (free polymerase and DNA) not strongly bound to the
beads. As controls, we prepared tethered transcription complexes using DNA and T7 RNA
polymerase with only one or neither of the two modifications. The resulting in vitro transcription
reactions with DNA encoding RNA-24 under high yield conditions, shown in Figure 3.6, confirm
that the absence of one or both of the modifications destroys RNA synthesis, both at low and high
salt concentrations, as expected.
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Figure 3.6. Effect of Strep Tag® II and nontemplate biotinylation on high yield tethered
transcription of RNA-24. A. Denaturing gel analysis (20%, 7M Urea) of high yield transcription
of RNA-24 using the corresponding constructs. B. Quantitative analysis of gel in A.
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Despite the high affinity of T7 RNA polymerase for its promoter, and the strategic preforming of the promoter complex before tethering to the beads, we expected that some enzyme
might couple to beads lacking nearby DNA or vice versa. Without a partner, on well-washed beads,
these species should be inactive in transcription. To test for enzyme immobilized without a
promoter DNA partner, we challenged an assembled and washed system encoding RNA-24Alt by
introducing in solution unmodified promoter DNA encoding RNA-34Alt. At low salt, RNA
polymerase without a locally (and functionally) tethered 24-Alt DNA partner should bind the free
34-Alt DNA and synthesize a 34 base RNA. The results in Figure 3.7 demonstrate this hypothesis
to be correct. While at low salt, both 24 base and 34 base RNAs are produced at levels similar to
that of untethered transcription, at high salt, only the 24 base RNA from the tethered DNA template
is observed.
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Figure 3.7. Challenging the Tethered System with Untethered Promoter DNA. A) Denaturing
gel analysis (20%, 7M Urea) of high yield transcription of untethered RNA-24Alt and untethered
RNA-34Alt and tethered RNA-24Alt and untethered RNA-34Alt at low and high salt
concentrations. B) Quantitative analysis of gel in A.
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To further confirm that (RNA-34-encoding) DNA-34 is binding to and reacting with
enzyme lacking a DNA partner, we increased the ratio of labeled 24 base encoding DNA-24 to
protein from 1:1 to 2:1, followed by a high salt wash to remove all unbound DNA. The results
shown in Figure 3.8 reveal an approximately two-fold increase in the overall RNA-24Alt
production for the 2:1 prep compared with the 1:1 prep, while RNA-34Alt production decreases
only slightly. This suggests that under these conditions, a significant portion of enzyme bound to
beads may not have a functionally tethered DNA nearby. Alternatively, biotinylated DNA-24
could be binding to an empty binding site in the tetramer, further increasing the DNA concentration
near tethered polymerase. Future development in this system will focus on optimizing binding
capacity.
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Figure 3.8. Saturating the free tethered enzyme with modified promoter DNA. A) Denaturing
gel analysis (20%, 7M Urea) of high yield transcription of tethered RNA-24Alt and untethered
RNA-34Alt from 1:1 and 1:2 E:D preincubation. B) Quantitative analysis of gel in A.
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3.3.6.

Use of tight binding pss[-5] and added salt allows in tethered transcription

The above demonstrates that enzyme bound to beads can transcribe from promoter DNA
free in solution, and that increasing salt concentrations in the transcription reaction results in a
preferential inhibition of enzymatic activity from free DNA over that from DNA co-tethered with
RNA polymerase, as shown in Figures 3.2, 3.3 and 3.4. We demonstrated in Chapter 2 that
strengthening promoter binding with a pss[-5] construct renders initiation less sensitive to salt.
Adding this condition to tethered transcription should further reduce the salt sensitivity of cotethered complexes, increasing the desired product formation.
As we noted in Chapter 2, using pss[-5] template DNA results in an overall decrease in 3’
self-extended RNA formation, even at high salt, due to the high affinity of polymerase to this
promoter. This is due to the fact that pss[-5] lacks sequence in melting region in the nontemplate
strand. As a result, polymerase does not exert some of its duplex promoter binding energy to melt
open the AT rich melting region. Since the off rate is reduced, while on rate stays the same, there
is a reduction in Kd, resulting in increased binding affinity. Since the longer impurities are never
formed, as a result of 3’ self-extension of encoded RNA, this also results in the overall increase of
the desired RNA products using pss[-5], and yield of encoded RNA increases even further at
increased salt concentrations.
We next tested the tethered system using pss[-5] similarly as we did in Figure 3.3 with the
hypothesis that encoded RNA-24 yield would increase. Untethered transcription behaves identical
as previously observed in Chapter 2. Detailed inspection of the tethered transcription profiles in
Figure 3.9 reveals that at low added salt, not all cis primed extension activity is prevented using
pss[-5], as extended products are observed, although not substantially. As expected, increasing the
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added salt concentration further prevents nucleotide addition at the 3’ end of RNA. This shows the
tethered system to work as expected with pss[-5] under low and high added salt concentrations.
pss -5
promoter

-5

Untethered

Tethered

[NaCl] (M)

0 0.1 0.2 0.3 0.4 0.5

Extended

0 0.1 0.2 0.3 0.4 0.5

[NaCl] (M)

24

Figure 3.9. pss[-5] promoter DNA at high salt generates more yield when used in tethered
system. A. Salt dependence of transcription profiles using pss[-5] for untethered and tethered
complexes analyzed by 20% acrylamide, 7M urea denaturing gel electrophoresis, labeled via
incorporation of [α-32P]ATP. The final concentrations of NaCl added to the standard reaction
mixture are shown.
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3.3.7.

The system is stable and reusable

In this system, Strep-T7 RNA polymerase and promoter nontemplate DNA are
immobilized on Strep-Tactin®XT magnetic beads. This allows that this bead-immobilized
transcription complex could be re-utilized for multiple rounds of transcription. To test this, we
carried out three rounds of transcription using the above bead tethered transcription complex, as
described in further detail in the Methods section, and illustrated as a scheme in Figure 3.10A.
Results in Figure 3.10B show that there is a significant loss in overall transcription after each
round. We hypothesized that this could be due to washing off of the template DNA with each
round, as template DNA is only bound to the tethered system via the strong promoter contacts.
Although promoter binding is tight, off rates of the enzyme are fast (90–92). This suggests that
with each round of transcription, it is not unreasonable to expect some template DNA to wash off
of the tethered system if promoter contacts are lost during the off states.
With the observation that there is significant loss in overall transcription at each round, we
hypothesized that strengthening promoter contacts might allow greater persistence of the complex
on washing. In the two domain model of the 17-base pair consensus T7 promoter, the duplex
recognition element (responsible for binding) stretches from position -17 upstream to position -5,
while the AT rich melting region (required for optimal catalysis) is situated between positions -4
and -1 (71). Part of the binding energy from the strong duplex binding interactions upstream of
(and including) position -5 is used to institute conformational change in the downstream DNA,
essentially predicted to melt bases from position -4 to about +3 (70, 93). As a result, the enzyme
binds a partially single stranded promoter DNA that has no bases downstream of position -5 in the
nontemplate strand (referred to here as pss[-5]) at least four times tighter than it binds double
stranded (or pss[+2], as used here) promoter (70, 93). With significantly slower off rates (90–92)
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and strengthened promoter binding, use of the pss[-5] promoter in the tethered system should
reduce loss by washing and result in greater overall retention of transcription activity after each
round of transcription.
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Figure 3.10. The tethered system can be reused. A) Reusability experimental order scheme.
After 2 h of “Use 1,” the reaction solution was removed, and a new substrate NTP solution was
added to initiate a 2 hr “Use 2” reaction (and repeated to initiate a 2 hr “Use 3” reaction). B)
Fifteen percent polyacrylamide denaturing urea gel stained with SYBR Gold Nucleic Acid Gel
Stain. Transcription profiles at low (0 M) and high (0.4 M) added NaCl for tethered transcription
of RNA-24 using pss[+2], analyzed as in Figure 2. C) Fifteen percent polyacrylamide denaturing
urea gel, stained with SYBR Gold Nucleic Acid Gel stain. Transcription profiles at low (0 M)
and high (0.4 M) added NaCl for tethered transcription of RNA-24 using pss[-5].
Comparison of the results in Figure 3.10C with those in Figure 3.10B confirms that use of
the pss[-5] construct significantly increases the reusability of the tethered system, at both low and
high salt concentrations. The gel analysis compares the products from each reaction cycle, using
the template encoding RNA-24, under both low (0 M) and high (0.4 M) added salt conditions, and
nontemplate DNA pss[+2] and pss[-5] respectively. The overall transcription yield decreases with
each cycle using pss[+2], and is nearly lost by round 3. In contrast, using pss[-5] DNA, the overall
transcription yield at each added salt concentration remains reasonably constant through three
rounds of washing and reuse. The system can be used at least three times (more rounds were not
tested), with essentially no loss in yield, by simply removing the product and adding transcription
buffer with fresh NTPs.
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3.4 DISCUSSION
Transcription in vitro by T7 RNA polymerase is a long-established method to synthesize
RNAs of diverse lengths and sequences, due to the promoter specificity and robust nature of this
system(20). Over the past 30 years, researchers have noted non-promoter driven activities of this
enzyme that contaminate the product pool with other than encoded RNA products, often termed
incorrectly as non-templated additions (20, 38–40). The quest for high yield RNA synthesis only
exacerbates the production of undesired, longer products (32) As high concentrations of encoded
RNA accumulate, T7 RNA polymerase binds RNA at its 3’ end and self-extends via cis primed
extension, now independent of the promoter.
High yield RNA synthesis efforts to date have focused on a two-step approach: 1) high
yield transcription using T7 RNA polymerase, followed by 2) (sometimes extensive) purification
of the encoded RNA using gel or chromatic purification methods. High yield conditions drive
primer extension, resulting in the correct length RNA product to get converted into heterogeneous,
longer than desired double stranded RNA contaminants. The very nature of high yield reactions
leads directly to longer, double stranded impurities and reduces the encoded RNA yield. This
process is sequence dependent, and in cases where the encoded RNA product does not significantly
participate in cis primed self-extension, gel electrophoretic or chromatographic purification
methods may be adequate to address the purity problem. However, each purification step generally
reduces overall product yield. Moreover, electrophoretic or chromatographic purification
approaches have highest success for relatively short RNAs. Preparative purification of longer RNA
(e.g., separating an encoded 300 base RNA from products extended by 20-30 bases) is often
difficult, if not impossible. With increased emphasis on mRNAs many kilobases in length, the
problem becomes increasingly difficult.
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The goal then is to prevent the rebinding of the synthesized RNA from the outset, to then
prevent the RNA-primed self-extension that leads to longer impurities. Noting that high ionic
strength inhibits all polymerase-nucleic acid interactions, we introduce here a novel in vitro
transcription method, transcribing at high salt to limit RNA product rebinding. To restore promoter
binding and initiation of transcription we co-tether promoter DNA and T7 RNA polymerase to
beads. Specifically, we co-tether Strep-T7 RNA polymerase and biotinylated promoter DNA to
Strep-Tactin®XT beads, bringing the enzyme in close proximity to its promoter to restore promoter
binding, even at high ionic strength. This results in overall higher yields of the desired RNA at
greater initial purity, reducing the need for subsequent (and low yield) purification steps.
3.4.1

Tethering plus salt leads to improved transcription purity and yield.

Increasing salt concentrations leads to complete inhibition of all enzymatic activity in the
untethered system, as shown in Figures 3.3, 3.4 and 3.5. In the tethered system, high salt inhibits
only the undesired cis-primed extension activity of T7 RNA polymerase, while allowing promoterdirected transcription. This reflects as a dramatic decrease of the longer, double stranded
impurities. Since production of the longer double stranded products derives from and therefore
consumes encoded-length RNAs, tethered system recovers higher yields of the desired (directly
encoded) product. As expected, at sufficiently high concentrations of added salt, promoter driven
transcription begins to be inhibited, even for the tethered system. For these constructs and these
conditions, a practical optimum of about 0.3 M added NaCl provides a good trade off of purity vs
yield. While these experiments have been carried out on relatively short RNAs, the almost identical
behavior of 24 and 34 length encoded transcripts argues that this result should be generalizable to
any length RNA (e.g., mRNA and lncRNA).
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3.4.2

Bead co-localization renders transcription resistant to salt

To characterize the salt dependence of promoter-driven transcription in the (relative)
absence of primer extension, we used a sequence, RNA-24Alt, previously observed to yield less
of the resolvable primer extended products(32). The results in Figure 3.4 show that while in the
untethered system, overall transcription is inhibited progressively with increasing added NaCl, the
tethered system continues to generate high yields of RNA-24Alt at moderate salt concentrations.
Note that at 0.1 M added NaCl, encoded RNA yield increases somewhat for both untethered and
tethered transcription systems, when compared to 0 M added NaCl. As discussed earlier, this
observation suggests that this RNA sequence is in fact subject to primer extension, but to a lower
extent and in a more dispersed heterogeneous (and therefore less readily visualized in a gel)
manner. Thus, even in an untethered system, low salt concentrations may reduce primer extension
with limited effect on promoter binding and initiation.
As the titration approaches 0.3 M added NaCl, the tethered system reaches maximal yield
of encoded length RNA, while the untethered system is inhibited significantly. At 0.4 M added
NaCl, the overall yield in the tethered system starts to drop, as the effect of high salt on inhibiting
even promoter-driven transcription becomes significant. This behavior parallels the results
observed for RNA-24 in Figure 3.3. For practical consideration, users can determine the optimal
concentration of added salt, depending on their RNA sequence, targeted degree of purity, and
desired yield.
3.4.3

Generality of the system

The characterization experiments shown in Figures 3.3 and 3.4 have been carried out on
relatively short RNAs 24 bases in length. To test the generality of the system, we used a DNA that
encodes a 34 base RNA (RNA-34) and carried out transcription using the tethered system. The
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results in Figure 3.5 exhibited similar characteristics in terms of transcription profile, salt
sensitivity and overall transcription yield. The similarity in transcription trends in 24 base and 34
base encoding tethered systems suggest these characteristics to be generalizable for other RNA as
well. The synthesis here of relatively short 24 and 34 base RNAs, allows precise analytical
characterization of both yield and impurities, but since conversion to a fully stable elongation
complex is complete by about 9-10 bases, we fully anticipate that this system can be extended to
much longer RNAs. Thus, this system should be readily used in the synthesis of CRISPR guide
RNAs, long noncoding RNAs, and mRNA.
3.4.4

Stability of the system

In RNA therapeutics applications, high yields of pure RNA are needed for research and
drug production purposes. In order to achieve high yields, researchers routinely carry out in vitro
transcription using T7 RNA polymerase for long hours under high RNA generating conditions(20,
23, 67, 94). Production under those conditions results in the generation of longer, double-stranded
impurities, which then requires extensive purification to recover only the encoded RNA(61–63,
95–97). At long RNA lengths, purification methods do not have the resolution to eliminate all
impurities (for example, separating a 2,000 base transcript from a 2,040 base impurity) and
purifications lead to a loss in yield. Moreover, since longer, double-stranded impurities are
generated via the extension of correct length, encoded RNA, the synthesis itself leads to a loss in
yield of the intended length product. The approach outlined here improves yield in both respects.
As the needed overall yield increases, as in therapeutic production, economic
considerations play a significant role in the design of synthesis approaches. Earlier studies have
described approaches to reuse DNA in transcription reactions. In one such approach, Davis and
colleagues tethered synthetic DNA to a solid surface and claimed 15 rounds of transcription using
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the same DNA, with the ability to store the system between rounds(58). In that system, however,
RNA polymerase must be added at each round; but more importantly, the polymerase is untethered and, as in solution reactions, as RNA product accumulates, primer extension will occur,
lowering purity and target RNA yield. Thus, while template DNA is reused, that approach is not
expected to improve the profile of the RNA generated in high yields.
The system described here is fundamentally different, in that it tethers both promoter DNA
and T7 RNA polymerase, in proximity, to magnetic beads and carries out transcription at high salt,
so that cis-primed extension activities are inhibited, resulting in an increase in overall yield and
purity of the encoded RNA. To further improve the yield of this system, we reused the beads for
multiple rounds of transcription, using the same DNA and enzyme, but additionally strengthening
promoter binding by use of a partially single stranded promoter construct. Comparing the results
in Figures 3.10B and 3.10C, strengthening promoter contacts using pss[-5] indeed helps retain
template DNA during washing and allows at least 3 repetitions of 2 hour reactions. When
compared with the routine (untethered) transcription reaction profile seen in Figure 3.3A, the
overall transcription yield of the encoded RNA is improved dramatically. This new system offers
dramatic improvements in encoded RNA yield and purity.
3.5 SUMMARY
In summary, the approach described here yields substantial improvements in RNA
synthesis compared with the typical approaches of the past. We demonstrate a novel approach to
in vitro transcription that prevents formation of longer than encoded, double stranded impurities
observed in high yield transcription reactions. With this system, T7 RNA polymerase activity is
exclusively promoter specific, with the inhibition of non-promoter specific activity (including
RNA self-primed extension). The near elimination of primer extended products that typically occur
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in high yield transcription reactions improves purity dramatically, while eliminating the extension
of correct length RNA increases the overall yield of the desired RNA product. This approach
further allows easy separation of product from RNA polymerase and from the templating DNA,
while allowing for re-use of these components.
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DNA sequences and constructs used in Chapter 3

A

5’-AATTAATACGACTCACTATAGG-3’

NT pss[+2]

5'-5BiosG/iSp18/TTTTTAATTAATACGACTCACTATAGG-3' NT-Biotin pss[+2]

Template Strands

5'-5BiosG/iSp18/TTTTTAATTAATACGACTCAC-3'

NT-Biotin pss[-5]

Nontemplate
Strands

Table A2.

24 3’-TTAATTATGCTGAGTGATATCCTCCATCATCTCCACTTCTAAAT-5’
24Alt 3’-TTAATTATGCTGAGTGATATCCTCCATGATGCAGCTGCGTAAAT-5’
34 3’-TTAATTATGCTGAGTGATATCCTCCATGCTGAGCGTGCATCTCCACTTCTAAAT-5’
34Alt 3'-TTAATTATGCTGAGTGATATCCTCCATACTGAGCTTTGATGCAGCTGCGTAAAT-5'

B
5BiosG
5’ Biotin with standard
C6 linkage

iSp18
18-atom hexa-ethyleneglycol spacer

*Consensus promoter sequence shown between dashed lines
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CHAPTER 4
NOVEL METHODS FOR THE AFFINITY PURIFICATION OF ENCODED RNA
4.1 INTRODUCTION
T7 RNA polymerase transcription in vitro is a well-established enzymatic synthesis method
to efficiently produce high yields of RNA longer than 20-50 nt (20, 23, 66, 67). However, as noted
in Chapter 1, the purity is often not good, as polymerase participates in non-promoter specific
activity that leads to size and sequence heterogeneity at the 3’ ends (30). In addition, polymerase
can produce short RNAs of 2-9 nt long via abortive cycling (20, 37, 98). Furthermore, DNAs used
in these transcription reactions may get degraded during storage and use, and such shorter
templates may encode RNAs shorter than desired length.
Purification of enzymatically synthesized
RNA is routinely done by gel or chromatographic
purification methods that have been around for
the past 30+ years (63, 96). These methods are
arduous, time consuming and often result in a

Common impurities in RNA synthesis
• Abortive RNAs (2-15 bases)
• Less than full length RNAs (n-i)
o From internal termination
o From degraded DNA templates
• 3’ double stranded extensions (n+i)
o From (self) cis-priming
o From trans-priming

massive loss in yield. In addition, we recently showed through RNA-seq data that the most
abundant product is often not the correct one, such that purifications that focus on the most
abundant product may be purifying the wrong product (32)! In addition, gel analyses are prone to
showing a product pool that “looks” pure to the naïve eye, even if the sample contains relatively
large amounts of widely dispersed shorter and longer impurities. For mRNA used in RNA
therapeutics research, impurities in in vitro T7 RNA polymerase generated mRNA have been
reported to induce an unintended immune response and may have potentially fatal results if
administered in therapies (69).
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Here, we develop a simple affinity purification method using capture DNA immobilized
on magnetic beads to purify high yields of encoded RNA, as shown in Figure 4.1. In this use, the
capture DNA has sequence complementarity to the 3’ end of the encoded RNA and is immobilized
on beads via covalent linkage or the strong streptavidin-biotin interaction. This method allows the
purification of only encoded RNA (n) by capturing it on magnetic beads, while washing away the
other RNAs (abortives, truncated RNAs, primer extended RNAs) and transcription reagents
(promoter DNA, polymerase, NTPs, Mg(II), pyrophosphatase, RNAse inhibitor murine) in one
simple step.
Transcription Products

Beads

immobilized capture DNA

n

-3’

target sequence

3’-

n+i

3’-

n+i

target sequence

n
n-i
n-i
abortives

-3’
-3’

-3’
-3’

3’-

n+i

Wash

n+i
n-i
n-i
abortives

3’-3’
-3’
-3’

NTPs
polymerase

promoter DNA

NTPs
PPi
polymerase

promoter DNA

PPi

Figure 4.1. Design of an affinity capture RNA purification method. Bead immobilized capture
DNA as an affinity tag purifies only the desired RNA, while all other RNA products and
transcription reagents and are washed away.
4.2 MATERIALS AND METHODS
4.2.1.

Reagents

DNA oligonucleotides used in transcription reactions were purchased from Integrated
DNA Technologies (IDT). DNA and RNA sequences and constructs used in this chapter are shown
in Table A3. The following buffers were optimized in house and used where indicated.
High yield transcription buffer contained 30 mM HEPES, 40 mM magnesium acetate, 25
mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8, 10 units/ml pyrophosphatase
(New England Biolabs, M2403L). Wash buffer contained 0.5 M NaCl, 20 mM Tris-HCl (pH 7.5),
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1 mM EDTA. Low yield transcription buffer contained 30 mM HEPES, 15 mM magnesium
acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8. Elution buffer
contained 10 mM Tris-HCl (pH 7.5), 1 mM EDTA.
4.2.2.

T7 RNA polymerase

His tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying
the plasmid pBH161; purified and characterized as previously described (29).
4.2.3.

Transcription reactions

All reactions were performed using partially single-stranded DNA constructs, in which the
nontemplate DNA oligonucleotide extends downstream only to position +2 (NT+2), unless noted
otherwise. All ‘high yield’ transcription reactions were carried out in the presence of 2 μM each
of nontemplate and template DNA oligonucleotides, 7.5 mM of each NTP, and 1.5 μl T7 RNA
polymerase Mix™ (New England Biolabs) in an overall 20 μl reaction volume at 37°C for 4 h
(unless noted otherwise in the manuscript). High yield transcription reactions in the presence of
capture DNA additionally contained 400 μM (unless noted otherwise) capture DNA.
4.2.4.

DNAse I reactions

All DNAse I (New England Biolabs) reactions were performed according to protocol
provided by NEB.
4.2.5.

RNA self-primed extension reactions

Reactions with synthetic RNA, in the absence of promoter DNA, were conducted with 25
μM synthetic RNA in the presence of 0.5 μM T7 RNA polymerase and 0.4 mM each of guanosine
triphosphate, cytidine triphosphate, adenosine triphosphate (ATP) and uridine triphosphate.
Reactions were carried out at 37°C for 5 min in low yield transcription buffer. For self-primed
extension reactions in the presence of dual capture DNA, or both dual capture DNA and universal
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sequence, DNA oligonucleotides, dual capture DNA contained 3′ amino modification and one or
both oligos were added to reaction mixtures to a final concentration of 25 μM.
4.2.6.

Gel electrophoretic analyses

Reaction products were analyzed with 20% polyacrylamide, denaturing (7 M urea) gel
electrophoresis. For Figures 4.3, 4.4, 4.16, transcribed RNAs were labeled by including [α-32P]
ATP (PerkinElmer) in the reaction mixture (without reducing the concentration of ATP). For all
other figures, RNAs were visualized by SYBR™ Green II RNA Gel Stain (Invitrogen).
4.2.7.

Bead binding and elution experiments

Magnetic bead experiments were carried out using Oligo d(T)25 Magnetic Beads,
Streptavidin Magnetic Beads (both NEB) and Strep-Tactin®XT beads (IBA Lifesciences), as
indicated.
4.2.8.

Other reagents

T4 DNA polymerase, Phi29 DNA polymerase and DraI were purchased from New England
Biolabs and their respective protocols were adapted from their provided datasheets. CircLigaseTM
was purchased from Lucigen and used according to the provided data sheet. DNA ladder was
purchased from IDT and they mark 100 nt through 20 nt in length at 10 nt intervals.
4.3 RESULTS
4.3.1.

Capture purification post synthesis

In order to test that bead immobilized capture DNA can affinity purify only encoded RNA
from a pool of RNA products, we used a streptavidin magnetic bead to immobilize a 5’ biotinylated
capture DNA on, as shown in Figure 4.2A, where capture DNA had sequence 17 nt
complementarity to the 3’ end of RNA-24. We chose a BioTEG functionality that has a TEG
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(triethylene glycol) linker to limit steric hindrance for efficient DNA binding and RNA capture
and added amino modification at the 3’ end to prevent undesired extension by polymerase. This
capture DNA is called Capture DNA-24. We carried out transcription for RNA-24, a 24 base RNA
known to participate substantially in cis self-primed extension, as shown in Figure 4.2B,
transcription pool. In high yield transcription reactions, 3’ primed self-extension from this RNA is
significant; almost all the encoded RNA-24 extended to longer, double stranded impurities. In
order to have a heterogeneous RNA pool including RNA-24 and longer impurities, we therefore
carried out transcription under low yield conditions. After transcription, we incubated the
transcription product pool with magnetic bead-immobilized capture DNA, as shown in Figure
4.2A. We hypothesized that from a pool of heterogeneous RNA, only the desired RNA (RNA-24)
would bind to streptavidin magnetic beads, while transcription byproducts like longer double
stranded RNA, intermediate length RNA, and abortive RNA would come away in the bead wash.
Figure 4.2A shows the hypothesized scenario, where RNA-24 is captured by bead immobilized
capture DNA, whereas other products and reagents are washed away in solution. In Figure 4.2B,
the heterogeneous transcription pool is shown in lane 1 as “Transcription Pool”, where RNA-24,
and longer impurities are abundant, as expected. After incubating the transcription pool with the
bead immobilized Capture DNA-24, the bead supernatant was removed, as shown in Figure 4.2B,
“Unbound”. Next, beads were washed once with wash buffer, as shown in Figure 4.2B, “Wash”.
Lastly, beads were resuspended in wash buffer to visualize all RNA that was “Bound” on the
beads. As expected, while longer, partially double stranded RNA impurities are washed away in
the supernatant (“Unbound”), only encoded RNA is captured via the Capture DNA-24
immobilized on streptavidin magnetic beads (“Bound”). There is a small leakage of RNA-24 in
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the washing step (“Wash”), as the bead capacity may be too small to be able to bind all the RNA24 generated in this transcription reaction, but the majority remains bound to the beads.
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Figure 4.2. Purification of RNA-24 post transcription using capture DNA immobilized
streptavidin beads. A. Scheme of streptavidin magnetic bead tethered capture DNA collecting
desired RNA post transcription. Capture DNA with a 5’ biotin tag and TEG linker has sequence
complementarity to 3’ end of RNAn and is bound to streptavidin magnetic beads. B. Low yield
transcription of RNA-24 shown as “Transcription Pool”; supernatant washed shown as
“Unbound”, second wash shown as “Wash”; bead captured RNA-24 and capture DNA affinity
tag shown as “Bound”.
4.3.2.

Capture during synthesis

While this approach can specifically purify full length RNA from a reaction, it does not
prevent the wasteful conversion of correct length RNA to longer, double stranded product during
transcription. We have recently demonstrated that addition of a similar capture DNA to the
transcription reaction sequesters the 3’ end of the (encoded) RNA to prevent primer extension (47).
It seemed reasonable then to couple that approach with the current approach. In this case, the
capture DNA would be biotinylated, and pulled away after transcription with streptavidin beads.
Figure 4.3 shows in the absence of capture DNA during transcription, RNA-24 and longer
impurities are formed at high yields, as expected. When transcription is carried out in presence of
biotinylated capture DNA-24, formation of longer impurities is prevented. After transcription, the
RNA pool (with biotinylated capture DNA-24 in solution) was incubated with streptavidin beads
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and the beads were then washed. As above, the correct RNA-24 product is bound on the beads,
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Capture
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Figure 4.3. Capture & purification of RNA-24 during transcription using capture DNA-24 beads
Transcription in presence and absence of capture DNA (Transcription, -, + capture) and the
purification of encoded RNA-24 (and intermediates) from the transcription pool after
incubating with streptavidin magnetic beads. RNA-24 bound to the beads shown as “Bound”;
what washed away shown as “Unbound”.
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Note in Figure 4.3 that intermediate length (n-i), but not short abortive, products are copurifying with the correct length products (it is thought that these products arise from failure to
fully complete the transition from initiation to elongation). Since the full-length product in this
experiment is only 24 bases in length, and the capture DNA-24 is complementary to the 3’ terminal
17 bases of the encoded RNA, an encoded 15mer, for example, would have 8 bases of
complementarity with the capture DNA. It appears that under these conditions, this may be
sufficient for at least some functional capture affinity. This suggests that for longer RNAs, while
these 12-15mer products will not co-purify, products several bases short of full length may. In
cases where slightly shorter than full length RNAs are problematic, users may need to
experimentally titrate the length of the capture DNA to optimize capture of full-length RNA, while
not capturing shorter products.
4.3.3.

Generality of the approaches

The above experiments were carried out with a very short RNA sequence. In order to test
the method for RNA of varying lengths and sequences, we repeated the experiments of Figure 4.3
on a DNA template (DNA-34Alt) encoding RNA-34Alt. This sequence participates in 3’ selfextension activity much less than RNA-24. The encoded RNA is 34 nt long, and the sequence
specific affinity tag is the same length as in Figure 4.3, but different in sequence to capture this
sequence RNA at its 3’ end. The results presented in Figure 4.4 demonstrate that in the absence of
capture DNA-34Alt, two distinct bands around 34 nt are observed. We hypothesized these are n
and n+1 or n+2 products due to their close proximity in gel migration. There are also some
extended products, but at a population significantly less when compared with the results in Figure
4.3, since this RNA-34Alt participates in 3’ self-extension activity much less than RNA-24. Upon
addition of the capture DNA-34Alt in the transcription mix, as nascent RNA-34Alt binds the
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capture DNA-34Alt at its 3’ end, the small amount of cis primed extension activity that occurs for
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Figure 4.4. Capture DNA Purification of RNA-34Alt. Transcription in presence and absence of
capture DNA-34Alt (Transcription, -, + capture). Purification of encoded RNA-34Alt (and
intermediates) with streptavidin tethered capture DNA-34Alt. RNA-34Alt is bound to the beads
“Bound” and all else was washed away in solution (“Unbound”).
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Note that the relative absence of longer primer extended products from this template allows
resolution of n+1 and n+2 products migrating just above the expected band. The results in Figure
4.4 show a substantial reduction in n+i product, as expected if these arise from the same primer
extension mechanism. Upon incubation with the streptavidin beads, only correct RNA-34 product
is purified away from the transcription mixture (lane 3), and the rest is washed away with the
supernatant. However, the same problem observed with the unintended purification of 12-15mer
intermediate products are also observed here. Future studies will characterize this more fully,
including the screening of buffers, temperature, and capture sequence length for more stringency
in binding.
4.3.4.

Increasing the capacity of the system

While streptavidin beads served well in demonstrating proof of concept for our affinity tag
purification system demonstrated in Figure 4.1, the yield of RNA is limited stoichiometrically by
the biotinylated DNA binding capacity of the streptavidin magnetic beads.
It is reported these streptavidin magnetic beads have capacity for binding 500 pmol single
stranded 25 bp biotinylated oligonucleotide per mg of beads. In order to efficiently capture &
purify encoded RNA during transcription 400 µM capture DNA was reported as minimum
required amount for a 20 µL high yield transcription reaction (47). This means 16 mg of beads
would be required to purify only one transcription reaction efficiently. This is not cost-friendly,
and experimentally complex, as 16 mg of beads are physically near impossible to separate
magnetically from a 20 µL solution. While these beads are efficient for quick and small-scale
purification of RNA, they are not efficient in purifying high yields of RNA.
In order to overcome the capacity issue observed with streptavidin magnetic beads, we
used an alternative bead covalently coated with Strep-Tactin®XT. Strep-Tactin®XT is a
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specifically engineered variant of streptavidin and biotin is reported to have picomolar binding
affinity to Strep-Tactin®XT. In addition, Strep-Tactin®XT coated magnetic beads have very high
capacity: Strep-tag® II fusion proteins are reported to have 0.085 nmol/µL capacity beads (e.g.
25.5 ug of a 30 kDA protein). Since there were no reported number for DNA binding capacity, we
took this number as a ballpark estimate and tested for our own purposes in house.
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Figure 4.5. Capture DNA binding capacity of Strep-Tactin®XT beads. 200 pmol, 400 pmol, 800
pmol and 1.6 nmol capture DNA were bound on 2 µL Strep-Tactin®XT beads and supernatants
washed. “All” lanes represent all capture DNA before incubating with the beads, “Unbound”
lanes represent what washed away, and “Bound” lanes represent capture DNA bound on
beads.
We tested the capacity by binding increasing amounts of biotinylated capture DNA-24 (0.2,
0.4, 0.8, 1.6 nmol) to 2 µL Strep-Tactin®XT dry beads. Figure 4.5 shows that 2 µL dry beads has
the capacity to bind at least 1.6 nmol capture DNA-24. Previously published work demonstrated
that in order to inhibit the cis primed extension polymerase activity in high yield transcription
reactions, there needs to be 400 µM of capture DNA in a high yield transcription reaction mix to
bind the appropriate product RNA (47). This would translate to 4 nmol of capture DNA in a 10 µL
transcription reaction, meaning one would need to incubate 5 µL beads with 4nmol capture DNA
to prevent such extension activity. This is a reasonable amount of bead in a 10 µL solution,
especially when compared with the requirement of streptavidin beads
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Figure 4.6. Synthetic RNA-24 binding and elution on high capacity Strep-Tactin®XT beads.
Binding of synthetic RNA-24 on Strep-Tactin®XT bead immobilized capture DNA and its
subsequent elution by heating the complex to 40 °C for 2 min.
Having confirmed that these beads have substantially larger capacity than streptavidin
beads, at amounts sufficient to inhibit cis primed extension activity of T7 RNA polymerase, we
tested their RNA binding capacity. We incubated equal amounts of synthetic RNA-24 with StrepTactin®XT immobilized capture DNA-24. We bound 1.6 nmol RNA to Strep-Tactin®XT
immobilized 1.6 nmol capture DNA-24 by incubating them in wash buffer for 45 min in room
temperature. After, we separated the supernatants from the beads and collected for analysis, shown
as “Unbound” in Figure 4.6. Since there was no RNA in this lane, we concluded all RNA was
bound on capture beads. Next, we wanted to elute the RNA-24 from the beads using heat. Rough
predictions suggested a Tm of about 38 °C for the RNA:DNA hybrid. Therefore, we eluted RNA24 from the bead-bound capture DNA-24 by renaturing beads in elution buffer and heating to 40
°C for 2 min. However, elution of RNA-24 was only partial under these conditions. Most of the
RNA-24 stayed on the bead tethered capture DNA. This suggests that the elution step needs to be
further optimized.
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4.3.5.

Rolling Circle Amplification as a tool to improve binding sites per oligo bound

on beads
We hypothesized that if the oligo DNA binding capacity of non-porous bead systems are
too small to purify large quantities of product RNA from high yield transcription reactions, and if
the porosity of high-capacity beads may hinder the binding of long RNAs (such as mRNA), we
needed to invent a novel method to increase the RNA binding sites per capture DNA oligo bound
on beads. In order to improve the capacity of any bead, I invented a novel approach utilizing rolling
circle amplification to amplify binding sites available per oligo bound on beads.
Figure 4.7 demonstrates the design of a novel method developed to amplify binding sites
per oligo bound on beads. First, a 5’ phosphorylated template DNA is circularized using via direct
or splint ligation. Then, the circularized template DNA encoding the capture DNA sequence is
hybridized to an RCA primer DNA oligo that will be extended from its 3’ end. Phi29 polymerase
initiates rolling circle amplification from this primer, using circular DNA as a template to generate
a long linear DNA with repeated sequences of Capture DNA, as shown in Figure 4.7A. A starting
RCA primer is amplified to a long DNA with many capture DNA sites, so that high yields of
desired RNA can be bound for purification, as shown in Figure 4.7B. Figure 4.7C demonstrates
different strategies used in this work to immobilize the RCA primer (or the amplified RCA primer)
on solid support (magnetic beads). We hypothesized that the RCA primer could either be bound
on beads first, to allow for RCA reaction to take place on the beads, or the RCA reaction could be
carried out in solution first, and the amplified linear DNA could be bound to the beads of choice
after.
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Figure 4.7. Design of a novel method to improve capacity per oligo bound on beads. A. Rolling
circle amplification mechanism of capture DNA sequence that improves on binding sites per
starting capture DNA oligo. B. Rolling circle amplified capture DNA sequence binds high yields of
desired RNA. C. RCA primers selected to bind different magnetic beads via covalent linkage and
streptavidin-biotin interaction
4.3.6.

Rolling circle amplification of capture DNA sequence in solution

We first circularized a 5’ phosphorylated RCA Template 1 (68 nt), that had of 4 repeats of
the previously used 17 nt capture-DNA sequence using CircLigase®, as shown in Figure 4.8 and
4.9A. After successful circularization, we hybridized the circular RCA Template 1 with RCA
Primer 1 (31 nt) via the 17 nt complementarity and performed rolling circle amplification (RCA)
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reaction using Phi29 DNA polymerase for 1 h and 16 h. We also performed the same reaction
using Linear RCA Template 1 and RCA Primer 1. While the Linear Template 1 did not perform
rolling circle amplification, as expected, both 1h and 16 h RCA reactions using the Circular RCA
Template 1 had gooey consistency, indicating efficient amplification and gelation of the long
DNA. To further confirm the amplification, we stained the reactions with Sybr Green dye, as
shown in Figure 4.9B. Both 1h and 16h reactions using the Circular RCA Template 1 were stained
substantially more when compared with the negative controls, further confirming successful RCA
reactions.

3’ capture
complmt
sequence

3’ capture
sequence

CircLigase

biotin

streptavidin
magnetic beads

RNA
3’

3’

3’

3’

3’

Figure 4.8. Scheme of Rolling Circle Amplification of Capture DNA sequence and subsequent
immobilization on streptavidin magnetic beads. 5’ phosphorylated Linear Template 1 is
circularized using CircLigase®, bound with RCA Primer 1 and rolling circle amplified using Phi29
DNA polymerase. Amplified capture DNA is bound to streptavidin magnetic beads using
streptavidin-biotin interaction. High yields of encoded RNA is bound on the repeated capture
sites on the bead immobilized amplified capture DNA sequences
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Next, we tested if RNA-24 could successfully bind to this amplified capture DNA oligo.
In order to do this, we incubated the both 1 h and 16 h amplified capture DNA products with 8 µM
synthetic RNA-24. After hybridization, we performed brief RNAse H digestion for 30 min at 37
°C on these samples as shown in Figure 4.9C. As a negative control, we performed RNAse H
digestion on same amount of single stranded RNA-24 in solution, which showed no substantial
decrease in intensity, demonstrating that RNAse H indeed cannot digest free RNA in solution. We
then tested, as a positive control, digestion of 8 µM synthetic RNA-24when in complex with 20
µM DNA oligo that had the 17 nt capture DNA sequence (T-24). Results showed cleavage of
RNA-24, while the DNA intensity remained unchanged, as expected. Therefore, we confirmed
RNAse H cleaves RNAs in a RNA:DNA hybrid. Lastly, when 1 h and 16 h amplified DNA was
incubated with synthetic RNA, in presence of RNAse H, the nuclease cleaved all RNA in an
RNA:DNA hybrid, as shown in Figure 4.9C . Results shown in Figure 4.9C demonstrate
successful binding of RNA-24 on RCA amplified RNA primer.
4.3.7.

Binding the amplified capture DNA to streptavidin beads

Next, we incubated the RCA amplified capture DNA on streptavidin beads using the 5’
biotin tag and follow up with RNA incubation. We hypothesized that amplified, 5’ biotinylated
capture DNA will bind to the beads, and upon incubation with RNA-24, we will capture the
synthetic RNA in beads. However, results in 4.9D show that binding of this long RCA product to
NEB Streptavidin beads was not achieved, as all RNA-24 was washed away to solution, and not
bound on the beads. We treated the bead complex with DNAse I for 30 min at 37 °C to test if the
RNA was not denatured off from the beads. However, this did not show RNA bound on the beads
as well. Therefore, we hypothesized that the long and entangled DNA hid the biotinylated 5’ end
in its core.
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As an alternative approach, we tried to perform rolling circle amplification reaction on the
RCA primer after tethering the primer on the streptavidin beads. However, we were not able to
accomplish RCA on bead tethered primers (results not shown). We hypothesized that there was
steric hinderance on the bead tethered RCA primer, preventing Phi29 polymerase from efficient
amplification. It was evident that we needed to first optimize the RCA for amplified DNA length
so that it won’t end up tangling or turn into gel form.
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Figure 4.9. Circularization and rolling Circle Amplification of Capture DNA, followed by its
subsequent binding to RNA-24 A. Circularization of RCA Template 1 using CircLigaseTM and its
follow-up exonuclease treatment B. Rolling circle amplification of negative controls and circular
RCA template 1, stained with Sybr Green II C. Binding of RNA-24 to rolling circle amplified
capture DNA and RNAse H assay of RNA:DNA hybrids D. Binding of rolling circle amplified
capture DNA to streptavidin magnetic beads.
4.3.8.

Binding to dT(25) beads

As an alternative to immobilization by protein affinity we have also explored
immobilization using Oligo dT(25) beads, from New England Biolabs. These beads are routinely
used for small scale purification of mRNA from cell lysates and tissue via affinity to cellular
mRNA’s 3’ polyadenylated tail. Using this commercially available bead with covalently attached
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dT25 allows us to use the T25 oligo as an RCA primer, and extend it from its 3’ end using an RCA
template containing A25, as shown in Figure 4.10.

2. RCA
Amplification

1. Circularization

3’ capture
sequence

T25

A25

3. Dra1 Digestion

15 nt
15 nt

Figure 4.10. Scheme of Rolling Circle Amplification of Capture DNA sequence and subsequent
immobilization on dT(25) magnetic beads. 5’ phosphorylated Linear Template 2 is circularized
and rolling circle amplified using Phi29 DNA polymerase on T25 primer covalently tethered on
beads. Amplified capture DNA is digested using Dra1 for analysis.
In order to do this, we circularized RCA Template 2 DNA using either Circligase® or T4
DNA ligase, as shown in Figures 4.11A and 4.11B, respectively. We followed circularization with
Exo I and III digestion to get rid of any linear DNA left in solution. We observed multiple bands
of circularized DNA, suggesting different lengths of circular DNA formation as a result of linear
ligation of two or more template strands followed by circularization of these DNAs.
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Figure 4.11. Circularization of Linear RCA Template 2 using direct and splint ligation
techniques. A. Circularization of Circular CTRL template (provided by IBA Lifesciences as a
positive control) and Linear RCA Template 2, and their exonuclease digestion to digest noncircularized templates B. Circularization of Linear RCA Template 2 using T4 DNA Ligase and a
split DNA, and their exonuclease digestion to digest non-circularized templates.
Next, we hybridized a synthetic dT(25) DNA, as a mimic to the bead tethered T(25) DNA to
the circularized templates, and performed rolling circle amplification using Phi29 DNA
polymerase. In order to better visualize the long RCA product, instead of Sybr Green staining in
Eppendorf tubes, we used a restriction enzyme Dra1 that can digest double stranded DNA with the
recognition sequence TTTAAA. We included this recognition sequence in the RCA template DNA
2, so that we could cleave it at strategic positions as shown in Figure 4.10 and visualize digested
15 nt DNA in gel analysis. This way, we could also digest the RCA product from dT(25) oligo in
beads for visualization as well, since covalently bound amplified DNA would not dissociate from
bead using heat unlike the streptavidin-biotin interaction.
Since we previously observed DNA tangling and gelation in 1 h and 16 h reactions, we set
out to optimize the control DNA lengths by adjusting ddNTP/dNTP ratios to find the right length
of amplified DNA. We performed RCA amplification with increasing ddNTP/dNTP ratios and
digested the products using Dra I as shown in Figure 4.12. First, we checked DraI activity on a
duplex CTRL Template 1 that included the recognition sequence necessary for digestion. The
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sequence of the DNA predicts that digestion of the 30 base CTRL Template 1 will lead to 15 nt
DNA oligos. We did observe such digestion, but not at 100%, which showed that the enzymatic
activity was not high enough to digest all the products in the RCA reaction. However, we decided
to go forward with this method as a tool to confirm rolling circle amplification, since we only
needed to see a trend to make an assessment of the results and would not require 100% digestion
of the RCA product. Figure 4.12 shows that with increasing ratio of ddNTP/dNTP, there is a
decrease in the digested product that migrates around the 25 nt length. We hypothesized this band
to be the 15 nt band of CTRL template, so the higher migration of a digested DNA product could
be due to incomplete denaturation in gel running conditions. These results suggest RCA reaction
is performing well at 1/2000, 1/1000 and 1/500 ddNTP/dNTP ratios.
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Figure 4.12. Controlling rolling circle amplified DNA length by increasing ddNTP/dNTP ratios
and their analysis with restriction digest using Dra I. A control reaction using CTRL Template 1
with TTTAAA recognition sequence demonstrates efficient Dra I digest. Increasing ddNTP/dNTP
ratio shows decrease in the digested 25 nt product.

87

Having confirmed functional RCA in solution with new template and primer sequences
(RCA Template 2 and RCA Primer 2), we next performed RCA on NEB Oligo d(T)25 Magnetic
Beads, using the covalently immobilized d(T)25 as the primer. Similar to the design demonstrated
in Figure 4.1, we hybridized the circularized RCA Template 2 with the d(T)25 oligo covalently
tethered to magnetic beads. After hybridization, we carried out RCA reaction on beads at
increasing ddNTP/dTP ratios of 1/5000,1/1000 and 1/250. We expected the RCA efficiency to be
less on bead surface when compared to in solution, due to possible steric hindrance and the
limitation of low concentration T(25) oligo bound on these beads. The exact amount covalently
tethered on beads was not reported by NEB, but the beads are advertised for low capacity mRNA
purification, thus we expected it to be a possible limiting factor. After the RCA reaction, we
performed Dra 1 digestion on all samples, as before and visualized the digestion products on the
20% acrylamide denaturing polyacrylamide gel. Control reactions in Figure 4.13 demonstrate Dra1
to be active and able to digest the control reaction. Dra 1 digestion looks to be much less overall
when compared with solution RCA results in Figure 4.12, which was expected. Upon Dra 1
digestion, a new band is observed around 25 nt for RCA products from 1/1000 and 1/250
ddNTP/dNTP ratio reactions, suggesting that amplification was successful in these samples. We
have observed neither circular DNA, nor cut DNA for the 1/5000 lane. This is surprising, since it
was expected to be the longest RCA product. We hypothesized that the long RCA product may
not be denaturing to release the hybridized products into the gel front, as circular DNA and CTRL
Template 1 has disappeared as well. However, it could also be due to an experimental error.
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Figure 4.13. Rolling circle amplified DNA reactions on covalently bead immobilized T(25) DNA
primer with increasing ddNTP/dNTP ratios and their analysis using restriction digest Dra I. A
control reaction using CTRL Template 1 with TTTAAA recognition sequence demonstrates
efficient Dra I digest. Increasing ddNTP/dNTP ratio shows decrease in the digested 25 nt
product.
Having demonstrated the rolling circle amplification reaction using dT(25) magnetic beads
and Circular DNA Template 2, we went on to test the binding capacity of these amplified beads
by incubating them with RNA-24 at 90 µM. We incubated RNA-24 with the beads at room
temperature, and separated supernatants, shown as “Unbound” in Figure 4.13. We washed the
beads with wash buffer once, shown in Figure 4.14 lane “Wash”, and resuspended in wash buffer,
as shown in lane “Bound”. Results show that only a small fraction of 1-10 µM of RNA-24 was
captured by dT(25) beads, while the rest washed away or was never bound. This is not sufficient in
reducing cis primed extension activity in high yield transcription reactions, or to purify high yields
of RNA post transcription. Future experiments will focus on boosting rolling circle amplification
on these beads.
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Figure 4.14. Binding of synthetic RNA-24 on rolling circle amplified dT(25) magnetic beads. 90
µM of RNA-24 was incubated with rolling circle amplified dT(25) beads and unbound, washed
and bound species were analyzed on 20% denaturing PAGE, stained with Sybr Gold.
4.3.9.

Universal Purification System

To generalize the purification platform to be applied for any sequence of RNA, we
developed a “next generation” design for the Capture-DNA tethered bead system. As shown in
Figure 4.15, a “universal sequence” DNA oligo is assigned as the staple sequence that could be
used by the system by default. Each time an RNA sequence needs to be purified; the end user
orders a new “dual capture DNA” oligo. The dual capture DNA has a sequence complementarity
to the universal sequence DNA on one half, and to the RNA sequence to be purified on the other.
The universal sequence is tethered on magnetic beads for the pull-down assay. This method could
be used during (dual capture DNA would take the role of cis primed extension inhibitor) or post
transcription for sequence specific RNA purification.
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Figure 4.15. A universal capture DNA purification system. A. Universal sequence DNA is
immobilized on magnetic beads by its 3’ end. Dual capture DNA then has sequence
complementarity to both the universal sequence and to the desired RNA 3’ end. B. Universal
sequence DNA is immobilized on magnetic beads by its 5’ end. Dual capture DNA has sequence
complementarity to both the universal sequence and to desired RNA. To prevent primed
extension in (A) the 3’ end of the dual capture DNA is amino-modified and in (B) the 3’ end of
the universal sequence is amino-modified.
If dual capture DNA is used in the role of a cis primed extension inhibitor during
transcription, the 3’ end of the DNA would need to have an amine modification to prevent its
undesired extension by T7 RNA polymerase (this is straightforward and inexpensive). We also
realized that the direction of the dual capture DNA would have importance in the efficiency in
prevention of cis primed extension reaction. Since one direction would sit blunt to the 3’ end of
RNA, the other direction would be a template under the product RNA where 3’ end is exposed.
Although we would expose the 3’ end RNA for nonspecific extension activity in this direction, we
hypothesized such activity could be prevented by also adding the universal DNA in the
transcription solution, preventing exposure of single stranded DNA to act as template for
polymerase. Therefore, we tested two possible directions in the design of a universal system as
shown in Figure 4.15A and 4.15B.
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4.3.10.

Free 3’ RNA.

We first tested the model demonstrated in Figure 4.15A, where the universal sequence is tethered
on magnetic beads from its 3’ end. We then went on to test this system’s role as an inhibitor during
transcription reaction, due to its close relation to the previously published work where capture
DNA was used to sequester the 3’ end of RNA. We recognized that product RNA would not sit
blunt to capture DNA in this scenario, and dual capture DNA could be used as a template if
polymerase extended RNA from its 3’ end in a trans primed extension reaction. Therefore, we
used both dual capture DNA and universal sequence in the transcription reaction, so that their
hybridization would prevent any such templated extension activity.
In the presence of both oligos, we performed a 5-minute in vitro transcription generating
RNA-24 using T7 RNA polymerase. The first lane in Figure 4.16A shows the transcription pool
in the absence of dual capture DNA; two distinct RNA bands are observed indicating encoded
RNA-24 and 3’ self-extended longer impurities. In the presence of dual capture DNA 1 and
universal sequence 1, the cis primed extension products are no longer generated, however another
longer RNA product is observed. While bead pull down assay only purified the encoded RNA, this
longer product was generated and washed away from the beads, indicating it is probably free in
solution (not binding to the beads). We hypothesized that this is due to templated addition on the
3’ end of the RNA. After the RNA binds to the dual capture DNA 1, polymerase uses the dual
capture DNA as a template and extends on the 3’ end of the RNA, displacing it from the universal
sequence.
To further investigate what this band referred to, we incubated a synthetic RNA-24 with
the universal sequence DNA and dual capture DNA in the absence of promoter DNA and carried
out transcription, as shown in Figure 4.16B. A long band migrating to the same position in the gel
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was observed, likely the same band as observed before, indicating this band arose from promoter
independent activity of polymerase. Since the 3’ end of RNA is free, and the RNA is bound to dual
capture DNA, the most likely explanation is that the RNA was extended from its 3’ end. To further
inspect the nature of this product, we treated the sample with DNAse 1. Upon digestion of DNA,
we observed two new bands, one referring to the length of RNA-24, and other to a length not
observed before. This suggests the longer band was an RNA:DNA chimera, consisting of two RNA
strands and a short DNA strand binding them together. At this point, we could only speculate what
non-promoter specific activity caused this band, as strand jumping activity may have been taking
place as well. We are not sure of the mechanism, but we were sure that we needed to change the
direction of the universal DNA sequence to prevent the 3’ end of the RNA from extension.
To further investigate what this band referred to, we incubated a synthetic RNA-24 with
the universal sequence DNA and dual capture DNA in the absence of promoter DNA and carried
out transcription, as shown in Figure 4.16B. A long band migrating to the same position in the gel
was observed, likely the same band as observed before, indicating this band arose from promoter
independent activity of polymerase. Since the 3’ end of RNA is free, and the RNA is bound to dual
capture DNA, the most likely explanation is that the RNA was extended from its 3’ end. To further
inspect the nature of this product, we treated the sample with DNAse 1. Upon digestion of DNA,
we observed two new bands, one referring to the length of RNA-24, and other to a length not
observed before. This suggests the longer band was an RNA:DNA chimera, consisting of two RNA
strands and a short DNA strand binding them together. At this point, we could only speculate what
non-promoter specific activity caused this band, as strand jumping activity may have been taking
place as well. We are not sure of the mechanism, but we were sure that we needed to change the
direction of the universal DNA sequence to prevent the 3’ end of the RNA from extension.
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Figure 4.16. Universal capture purification of RNA-24 using method introduced in Figure 15A.
A. The effect of dual capture DNA 1 and universal sequence 1 on transcription of RNA-24 under
low yield conditions, and the subsequent capture purification of RNA-24 on streptavidin beads.
B. The effect of dual capture DNA 1 and universal sequence 1 presence near high yields of RNA
during transcription.
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4.3.11.

Blunt 3’ RNA.

Exploring the second option in Figure 5.15, we designed a new universal sequence 2 and
dual capture DNA 2 so that the 3’ end of product RNA will sit blunt to the 5’ end of the dual
capture DNA. We then we performed high yield transcription in the absence of any capture DNA,
as seen in the first lane in Figure 4.17. We then compared the effect of adding of dual capture DNA
1 vs dual capture DNA 2 during transcription on the product RNAs. When dual capture DNA 1
strand is added alone to the transcription reaction, polymerase participates in significant nonpromoter specific activity resulting in a large pool of heterogeneous, longer RNA products. Upon
DNAse 1 digestion, most products get cleaved, and a heterogeneous pool of RNA products are
observed. This is similar to the results we had seen in Figure 4.16, yet at an increased rate, since
the reaction was run under high yield conditions in Figure 4.17, while the experiment in Figure
4.16 was performed under low yield conditions.
Changing both sequence and direction of the dual capture DNA, we performed
transcription in the presence of dual capture DNA 2, as seen in Figure 4.17. Despite changing the
direction of the dual capture DNA, and leaving RNA with a blunt end, not all promoter nonspecific activities are prevented. There is another impurity: a longer band, present as a result of
this incubation. Upon DNAse treatment, these bands are digested, revealing a clean RNA-24
encoded product. While it is not clear what these other bands were, they could be products of nonpromoter specific activity of T7 RNA polymerase. While making the dual capture DNA strand sit
blunt to the 3’ end of the RNA helped prevent excess non-promoter specific activity of T7 RNA
polymerase, it did not avoid all such activity. From the results in 4.17, we concluded that the
universal affinity tag purification design was too complex to use such purification system during
a transcription reaction. Given the unpredictable non-promoter specific activities of polymerase
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and the number of free oligos in solution at high concentrations, we decided to not further pursue
this strategy for transcription.
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Figure 4.17. Transcription of RNA-24 under high yield conditions in the absence and presence
of dual capture DNA 1 and 2 and their consequent DNAse I treatment. Transcription under
high yield conditions generated RNA-24 and extended products sans dual capture DNA 1 or 2. In
presence of dual capture DNA 1, polymerase participates in significant non-promoter specific
activity, resulting in much longer extended products. Upon DNAse I treatment, most of such
bands get cleaved, leaving a heterogenous RNA product pool. In presence of dual capture DNA
2, some longer bands are observed, but the majority of product is RNA-24. Upon DNAse I
treatment, all other bands are cleaved except RNA-24.
4.4 DISCUSSION
Researchers across a wide swath of fields that use RNA require pure and high yields of
pure, correct sequence RNA. While solid phase chemical synthesis can generate RNAs <100 nt in
length (74), enzymatic synthesis in vitro by T7 RNA polymerase (23) is routinely chosen over
chemical synthesis to synthesize high yields of RNA of all lengths. In either case, product RNA
needs to be purified before used for downstream applications. Purification has always been carried
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out with either gel or chromatographic methods, which have their major disadvantages as
described earlier (49–53). In this chapter, we introduced a novel affinity purification method using
bead immobilized capture DNA to purify only desired RNA, while washing other RNA byproducts
(i.e. abortives, truncated products, longer impurities, and reagents) away.
4.4.1.

Capture DNA immobilized on magnetic beads

We designed a capture DNA that is complementary in sequence to the 3’ end of RNA-24
and immobilized it on magnetic beads by the strong biotin-streptavidin reaction. Based on
predicted melting temperatures (Tm’s), this capture DNA needed to be longer than ~15 nt to be
able to effectively capture product RNA in a RNA:DNA hybrid. As predicted, bead immobilized
capture DNA captured only the encoded RNA from a pool of diverse RNA products, as shown in
Figure 4.2. For the purification of high yields of correct RNA, this method would need to be carried
out in combination with one of the improved transcription reactions established in this dissertation,
or with a previously published transcription method. We combined the previously published
transcription strategy with our purification approach simply by carrying out transcription in the
presence of the capture DNA, and immobilizing of the RNA:DNA hybrid post transcription on
streptavidin magnetic beads. Results in Figures 4.3 and 4.4 showed that while this prevented the
formation of extended products, and successfully purified the encoded RNA by their capturing on
magnetic beads via the affinity tag, the intermediate RNAs also got co-purified as a result. In
addition, the capacity of the commercially available streptavidin beads was not enough to purify
high yields of RNA.
To improve the capacity, we used Strep-Tactin®XT, as this bead is coated with 6%
agarose, and therefore has higher capacity than the previously used streptavidin beads. As
expected, high yields of RNA was captured on beads. Only 5 µLof dry bead tethered with 4 nM
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of capture DNA oligo in a 10 µLtranscription reaction is predicted to be sufficient to inhibit selfextension if used during transcription Further improvement on elution conditions needs to be
performed for precise elution of RNA without denaturing the streptavidin protein coated on the
beads. One setback with the Strep-Tactin®XT beads could be that they are coated with 6% agarose
around a magnetic core, and thus may not apply well to very long RNAs (such as mRNA), as the
porosity of the beads may limit the ability of the RNA to reach the binding sites on the bead surface.
For stability and reusability, one can obtain paramagnetic beads with DNA covalently attached to
a non-porous bead surface. However, this design results in still lower binding capacity due to the
lack of porosity.
4.4.2.

Increasing the binding sites DNA oligo immobilized on magnetic beads

In a quest to improve the low binding capacity observed with streptavidin magnetic beads,
we developed a novel system to increase the RNA binding sites available per capture DNA oligo
bound on magnetic beads. We circularized a DNA and used it as a template to extend the capture
DNA attached on the beads by rolling circle amplification reaction. We showed that this method
is powerful and can bind high yields of RNA in solution, as demonstrated in Figure 4.9. However,
we were unable to bind the RCA-generated, long DNA capture strand to the streptavidin beads,
also shown in Figure 4.9. We hypothesized that either 1) the long DNA may be tangled in itself,
burying the 5’ biotin tag in its core or 2) the size of the RCA-generated DNA does not allow it to
enter the agarose pores.
To address the second concern, we next tried a different magnetic bead that has T(25) oligo
DNA covalently tethered on magnetic beads of low/no surface porosity. We used increasing
ddNTP/dNTP concentrations to control the DNA length distribution of the RCA reaction, and
tested for RNA binding. While we were able to perform RCA on the beads, as shown in Figure
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4.13, we only purified a small concentration of RNA, as shown in Figure 4.14. This showed that
the RCA efficiency on beads needed to be improved.
This strategy could be used during or post synthesis, but just like other strategies what
polymerase non-promoter specific activity polymerase may carry out is currently unknown.
Taking from the results seen in Figures 4.16 and 4.17, perhaps the RNA bound on the long capture
DNA oligo will be extended in a templated fashion, even if there are DNA oligos put in between
the binding sites to prevent such activity. For the moment, it would seem best to first perform an
improved in vitro transcription reaction (high salt tethered, or flow synthesis) and then follow up
that reaction with this purification protocol for efficient and robust RNA purification.
4.4.3.

A universal reagent for the affinity tag purification of desired RNA

We designed a universal system using a “universal sequence” tethered to magnetic beads
that allowed customization of capture DNA for purification different RNA sequences. We showed
in Figure 4.2 that capture DNA can purify only the encoded RNA from a pool of diverse products.
It is expected that the universal reagent approach would bring similar results. However, we only
worked on its effect as a purification agent during transcription reactions. Results in Figure 4.16
demonstrated that not having a free end at the 3’ end of the RNA caused substantial non-promoter
specific polymerase activity, resulting in the generation of an undesired long RNA:DNA chimera.
Although changing the direction of this dual capture DNA improved the non-promoter specific
polymerase activity substantially, it did not get rid of it completely, as seen in Figure 4.17. These
results showed that this purifications method may not be ideal to be used during transcription.
However, it can be very powerful for purification post transcription, in aiding customization for
diverse sequence of RNAs using the same universal purification platform. In order to achieve high
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yields of RNA purification, and to prevent its wasteful conversion to longer impurities, one would
need to use one of the improved transcription methods established in this dissertation first.
4.5 SUMMARY
In this research, we develop a novel affinity tag method for the purification of in vitro
transcribed RNA in high yields. Magnetic bead immobilized capture DNA is complementary to
the 3’ end of the RNA to be purified. We first demonstrate that the affinity tag can selectively
purify only the desired RNA from a pool of heterogeneous RNA products. We then show that the
capture DNA can be used during transcription, as previously demonstrated (47) to RNA selfprimed extension. We further improved this methodology by incubating the crude reaction mix
with streptavidin beads post transcription to purify only the desired RNA. We found that using
streptavidin beads has low capacity, making them inefficient in their application to high yield
transcription reactions. We observed this initial system may co-purify the intermediate RNA
byproducts as well. We improved on this fallback by using a higher capacity bead system. Strep
Tactin-XT® magnetic beads demonstrated to efficiently capture and purify high yields of synthetic
RNA.
These initial findings helped us understand the major challenge of the project: which is to
find a magnetic bead with high capacity to be able to purify large quantities of encoded RNA.
However, magnetic beads often lack the porosity required to enable high-capacity capabilities. For
this reason, I designed a novel capture purification method to improve the capacity of any bead
used for affinity purification of in vitro transcribed RNA. In this method, we improve the binding
capacity by using rolling circle amplification to increase the binding sites per DNA oligo bound
on beads. The capture DNA oligo sequence is repeated in tandem for many rounds, and encoded
RNA binds to these sites.
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Next, we developed a novel universal capture DNA purification system that could be used
for any sequence of RNA to be captured without having the researcher change the system to fit
their sequence needs. In this system, a “universal DNA oligo” with a fixed, universal sequence is
immobilized on magnetic beads by its 3’ end. “Dual capture DNA” has sequence complementarity
to both the universal DNA oligo sequence and to the 3’ end of the desired RNA to be purified. We
demonstrated that the method can indeed capture purify encoded RNA, as hypothesized. This
method is more suited for purification post transcription, since its presence during transcription
caused unexpected, yet notorious non-promoter specific polymerase activity.
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Reference Name
NT+2
Template DNA-24
Synthetic RNA-24
Capture DNA-24
Template DNA-34Alt
Capture DNA-34Alt
RCA Template 1
RCA Primer 1
RCA Template 2
RCA Primer 2
Splint DNA
CTRL DNA
CTRL Template 1
CTRL Template Complement
Universal sequence 1
Dual capture DNA 1
Universal sequence 2
Dual capture DNA 2

Sequence
5’ AATTAATACGACTCACTATAGG 3’
3’ TTAATTATGCTGAGTGATATCCTTATTCATCTCCACTTCTAAAT 5
5’ GGAAUAAGUAGAGGUGAAGAUUUA 3‘
3’-NH2-CATCTCCACTTCTAAAT-5’ BioTEG
3’ TTAATTATGCTGAGTGATATCCTCCATGCTGAGCGTGCATCTCCACTTCTAAAT 5’
3’-NH2-GATGCAGCTGCGTAAAT-5’ BioTEG
3' ATTTAGAAGTGGAGATGATTTAGAAGTGGAGATGATTTAGAAGTGGAGATGATTTAGAAGTGGAGATG (P) 5’
5’ TTTTGTGACCACAATAAATCTTCACCTCTAC 3’
3‘ AAAAAAAAAAAAAAATTTAGAAGTGGAGATGATTTAGAAGTGGAGATG (P) 5’
5’ TTTTTTTTTTTTTTTTTTTTTTTTT 3’
5' AAATCTTCACCTCTACTTTTTTTTTTTTTTT 3'
Sequence unknown, provided by IBA Lifesciences as + CTRL
3' AAAAAAAAAAAAAAATTTAGAAGTGGAGAT 5'
5' TTTTTTTTTTTTTTTAAATCTTCACCTCTA 3'
5’ GTGAGTGGAGGTGAGAGTGGAGATGGTTT 3’ (BioTEG)
NH2 3’ CATCTCCACTTCTAAATCACTCACCTCCACTCTCACCTCTACC 5’
BioTEG-5’ TTTTTTTTTTTTTTTTTTTTTTTTT 3’
NH2-3’ AAAAAAAAAAAAAAAAAAAAAAAAACATCTCCACTTCTAAAT 5’

Table A3.
DNA and RNA sequences and constructs used in Chapter 4
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CHAPTER 5
A NOVEL MICROFLUIDIC RNA MICROFACTORY GENERATES HIGH YIELD RNA
WITH SUPERIOR PURITY
5.1 INTRODUCTION
The mRNA therapeutics industry has finally evolved from being a “future promise,” to an
applicable therapy. The urgency of the COVID-19 pandemic has accelerated the establishing of
safe and effective RNA vaccines, putting a spotlight on what mRNA therapeutics can offer to the
world from vaccines to genetic diseases. Until recently, mRNA therapeutics was not an applicable
therapy and most researchers only produced small amounts of RNA sufficient for their research
purposes. Now, the field has matured into a treatment modality. In this new light, generating high
yields of pure RNA in an automated way emerges as a novel need of the industry.
Currently, all mRNA and most other RNAs are routinely generated by in vitro transcription
using T7 RNA polymerase. This is a simple, highly efficient and low-cost method to generate high
yields of long (and short) RNA (18, 20, 23, 66). However, in vitro transcription by T7 RNA
polymerase is a complex and multi-step process and the product profile is often heterogeneous due
to enzyme promiscuity (20, 25, 31, 32, 34, 37–39, 41, 42, 44, 45). While this enzyme can produce
high yields of desired RNA, it also produces short RNAs 2-7 nt in length (abortive cycling) (30,
46), and longer than directly encoded RNAs via a wide array of mechanisms explained in further
detail in Chapter 1.
Under high yield transcription conditions, when large quantities of RNA accumulate near
T7 RNA polymerase, the enzyme partakes in significant RNA rebinding and subsequent cisprimed extension activities (31, 32). As a result, the product profile is often contaminated with a
heterogeneous pool of partially and fully double stranded RNA products. As industry requires high
yields of RNA for various treatment modalities (such as mRNA vaccines), double stranded RNA
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byproducts are often the most cumbersome impurity in large-scale RNA production (60, 62, 65,
69). Therefore, while T7 RNA polymerase is praised for being an easy, low-cost method to produce
high yields of RNA, the quest for high yield only exacerbates the generation of long, double
stranded RNA impurities (31, 32).
RNA therapeutics companies such as Moderna and BioNTech routinely follow high yield
transcription with extensive HPLC purification(60–63) to rid the product pool of short and long
RNA impurities. In addition to routine purification, they also take advantage of other
methodologies, such as the use of synthetic nucleotides (e.g., pseudo (ψ)-UTP), to further prevent
the immune response caused by double stranded impurities (99–101). The limitations of current
purification methodologies and other immune response prevention techniques are explained in
further detail in Chapter 1.
In short, current methodologies for high yield RNA synthesis and purification, adopted
from protocols established decades ago, are simply not enough to carry the RNA therapeutics field
to where it can lead. Current protocols of transcription and purification need to be improved for
industrial scale, ultrapure RNA generation.
In Chapter 3, I introduced a novel high salt in vitro transcription method where T7 RNA
polymerase and promoter DNA are co-tethered on magnetic beads. I demonstrated that while high
salt dramatically reduces all nucleic acid-polymerase interactions, co-tethering T7 RNA
polymerase and promoter DNA in proximity on beads restores only promoter-driven transcription
and limits the RNA rebinding activity of polymerase. Using this method, only encoded RNA is
generated at high yields. The immobilized system is reusable up to at least three times, providing
further improvement in overall yield. Whilst this system is superior in terms of purity and yield to
the generic method, it can be further improved for automated use in industry.
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To prevent primed extension of accumulating RNA, we now aim to not allow the RNA to
accumulate near the enzyme from the outset. In this Chapter, I introduce a novel microfluidic in
vitro transcription device. The bead-tethered transcription system (established in Chapter 3) is
trapped inside the reaction chamber of a fluidics device. Transcription is carried out under
continuous flow, allowing product RNA to flow out of the device continuously, preventing its
accumulation near the polymerase. We expect this approach to reduce the production of longer,
double stranded RNA impurities substantially, even at low salt, while producing high yields of
encoded RNA. We predict this approach will revolutionize the large-scale generation of pure RNA
for industry and serve as a gateway for revolutionizing many other manufacturing methodologies
in biotech and pharma companies.
5.2 MATERIALS AND METHODS
5.2.1

Reagents

DNA oligonucleotides used in transcription reactions were purchased from Integrated
DNA Technologies (IDT). The following buffers in Table 5.2.1 were optimized in house and used
where indicated.

Component

Wash
Buffer

T7 RNA
Polymerase
Buffer

High Yield
Transcription
Buffer

HEPES, pH 7.8
Tris-HCl, pH 7.5
Magnesium acetate
Potassium glutamate
Tween 20
EDTA
Pyrophosphatase
NaCl

20 mM
1 mM
0.5 M

30 mM
15 mM
25 mM
0.05%
0.25 mM
-

30 mM
40 mM
25 mM
0.05%
0.25 mM
10 U/mL

Table 5.2.1. Transcription and wash buffers used in this study.
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5.2.2

T7 RNA polymerase

His-tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying
the plasmid pBH161; purified and characterized as previously described (29).
5.2.3

Strep-T7 RNA polymerase

In an earlier, unpublished work, an ATG start codon, the Strep-tag® II sequence
(WSHPQFEK) and a linker sequence (GGS) (followed by the T7 RNA polymerase gene) were
inserted between the Nco I and Hind III restriction sites in the plasmid vector pBAD HisA. Strep
tagged T7 RNA polymerase was expressed under the inducible control of the L(+) arabinose
promoter, and further purified using Strep-Tactin® protein purification resin from IBA
technologies.
5.2.4

Manufacturing of the Microfluidic Device Mold

Device designs were drawn on Adobe Illustrator. Photomask was printed at 20K DPI
resolution with clear field right reading down orientation (CFRRD) (Fineline Imaging, Inc).
After SU-8 2100 photoresist coated wafer was spun at 3000 RPM to a thickness of 100 µm, it was
pre-baked at 65°C and 95°C. Then, the photomask was covered over the coated wafer and exposed
to ultraviolet (UV) light with an exposure energy of 240 mJ/cm2 to crosslink the photoresist. After
exposure, it was baked again at 65°C and 95°C. The unexposed parts were removed by propylene
glycol monomethyl ether acetate (Sigma Aldrich).
5.2.5

Manufacturing of the PDMS-Glass Microfluidic Device

A 1 cm thick PDMS (Sylgard® 184 from Dow Corning®) was prepared by 10:1 ratio of
elastomer base to curing agent, degassed for 40 minutes in a vacuum chamber and cured on the
device mold for at least 2 hours at 80°C. The PDMS with the design imprint was cut from the
mold, inlet and outlet holes were punched. The PDMS was bonded to a glass slide by oxygen
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plasma treatment (Harrick Plasma Cleaner). The flow system was assembled by connecting tubes
directly to the inlet and the outlet. To interchange between different reagent flows to the inlet, two
Y-valves were connected prior to the inlet port to allow for reagent switching. Device features
were observed with Amscope 7X-45X Dual Lit 6W LED Trinocular Stereo Zoom Microscope and
images were taken with a 10MP USB 2.0 Color CMOS C-Mount Microscope Camera with
Reduction Lens attached.
5.2.6

Batch transcription reactions

High yield batch in vitro transcription reactions (1 h reaction in Figure 5.3.7B) were
performed with high yield transcription buffer in presence of 0.8 μM (each) of nontemplate and
template DNA, 0.8 μM T7 RNA polymerase and 7.5 mM of each NTP, in an overall 20 μL reaction
volume at room temperature. Low yield batch in vitro transcription reactions (5 min reaction in
Figure 5.3.7B) were performed with T7 RNA polymerase buffer in presence of 0.8 μM (each) of
nontemplate and template DNA, 0.8 μM T7 RNA polymerase and 0.8 mM of each NTP.
Transcription reactions were stopped by heat denaturation at 95 °C for 5 min.
5.2.7

Preparation of bead co-tethered system before packing

To assemble the promoter complex, equimolar (0.8 µM final) concentrations of
biotinylated nontemplate DNA, template DNA and Strep-T7 RNA polymerase were incubated at
4 °C for 30 min in T7 RNA polymerase buffer. Strep-Tactin®XT (5% slurry) beads were washed
with T7 RNA polymerase buffer three times and then incubated with the above enzyme-promoter
comple at 4 °C overnight in a rotator to form the tethered transcription system. After overnight
incubation, tethered transcription system was washed twice with wash buffer and once with T7
RNA polymerase buffer to rid the system of any untethered system components. 26 µL of a 1%
v/v bead slurry (MagStrep “type3” XT beads, IBA Lifesciences) netting approximately 0.26 µL
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packed beads tethered with 0.8 µM final concentrations biotinylated nontemplate DNA, template
DNA and Strep-T7 RNApolymerase of transcription complex were incubated in T7 RNA
polymerase buffer containing 10% PEG-8000 to homogenize the bead co-tethered system for
packing. All reactions were assembled with specific promoter DNA sequences as indicated in text.
5.2.8

Flow transcription reactions

In all flow reactions, low yield reaction conditions were used. Transcription was initiated
with the inflow of T7 RNA polymerase buffer containing 0.8 mM of each NTPs at room
temperature at flow rates and times as indicated in text. Fractions coming from the outflow were
collected every 5 minutes and heat denatured at 95 °C for 5 min.
5.2.9

Gel electrophoretic analyses

All reactions were analyzed by 15% polyacrylamide (19:1 acrylamide:bisacrylamide)
denaturing (7M) urea gel electrophoresis, labeled with SYBR™ Gold Gel Stain (Invitrogen) and
imaged with a Gel Doc Go Imaging System Blue Tray (Bio-Rad).
5.3 RESULTS
The goal of this study is to prevent the accumulation of encoded RNA near T7 RNA
polymerase and therefore eliminate RNA rebinding and cis-primed extension activities of
polymerase. Here, we establish a novel microfluidic in vitro transcription device that continuously
generates high yields of RNA and concomitantly carries it away from T7 RNA polymerase.
Transcription operates under continuous flow in a reaction chamber, where a bead co-tethered
transcription complex (established in Chapter 3) is physically trapped by an array of micropillars.
As transcription proceeds under continuous flow, promoter DNA and T7 RNA polymerase (bound
to beads) are retained inside the reactor chamber, while all products (including RNA) flow out
(while fresh reagents are continuously introduced). As product RNA is removed from the
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microfluidic device as soon as it is generated, its accumulation near T7 RNA polymerase is
prevented. We expect this novel approach to generate high yields of only encoded RNA, and
prevent the generation of longer, double stranded impurities.
5.3.1.

Design of a microfluidic in vitro transcription device

In order to trap the bead-tethered system established in Chapter 3 inside a microfluidic
device and still allow for efficient transcription and continuous outflow of product RNA, I first
designed a single inlet-single outlet PDMS-glass device with a single array of PDMS micropillars
near the outlet, as shown in Figure 5.3.1A. The micropillar array acts as a barrier to trap the beads,
while allowing free flow of product RNA away from the polymerase with continuous flow. In
order to trap the Strep Tactin-XT® beads that have an average diameter of 25 µm, the lateral
spacings between the micropillars are designed to be 20 µm (the micropillars are 40x50x100 µm
in width, length and height, as shown in Figure 5.3.1B). We hypothesized this to be sufficient for
efficient trapping of the beads, while still allowing continuous flow.
I designed the microfluidic device dimensions accordingly to accommodate the packing of
26 µL of a 1% v/v bead slurry (MagStrep “type3” XT beads, IBA Lifesciences) netting
approximately 0.26 µL beads (calculated value). The reaction chamber of the microfluidic device
that hosts all of the bead-tethered transcription complex is designed as 6.6 mm in length, 600 µm
in width and 100 µm in height, netting to about 0.4 µL chamber volume capacity, as shown in
Figure 5.3.1B. I selected channel height to be 100 µm, that is four times the bead diameter, in order
to preemptively prevent possible clumping of beads that could clog the inlet whilst loading the
beads.
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Figure 5.3.1. Design of a microfluidic transcription device. A. Scheme of a PDMS-glass
microfluidic in vitro transcription device. B. Design of the PDMS-glass microfluidic in vitro
transcription device. Transcription is initiated with the inflow of T7 RNA polymerase buffer,
containing NTPs. Beads (tethered with promoter DNA and T7 RNA polymerase system) are
trapped in reaction chamber by an array of micropillars. Product RNA, and other biproducts in
transcription buffer are flowed out as generated. Reaction chamber and bead dimensions are as
shown. C. Design of the bead tethered transcription complex. Strep-T7 RNA polymerase and
biotinylated promoter DNA are co-tethered on Strep-Tactin-XT® beads.
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5.3.2.

Fabrication of the microfluidic in vitro transcription device

We drew the microfluidic device design using Adobe Illustrator and printed the photomask
at 20K DPI resolution with clear field right reading down orientation (CFRRD) (Fineline Imaging,
Inc). After SU-8 2100 photoresist coated wafers were spun at 3000 RPM to a thickness of 100 µm,
photomask was covered over the coated wafer and exposed to ultraviolet (UV) light with an
exposure energy of 240 mJ/cm2 to crosslink the photoresist. The unexposed parts were removed
by treatment with propylene glycol monomethyl ether acetate (Sigma Aldrich).
A 1 cm thick polydimethylsiloxane (PDMS) (Sylgard® 184 from Dow Corning®) sheet
was prepared with a 10:1 ratio of elastomer base to curing agent, degassed for 40 min in a vacuum
chamber and cured on the SU-8 mold for at least 2 hours at 60°C. After the PDMS sheet with the
design imprint was cut from the mold, the inlet and outlet holes were punched, and the sheet was
bonded to a glass slide by oxygen plasma treatment (Harrick Plasma Cleaner). The flow system
was assembled by connecting tubes directly to the inlet and the outlet holes. To interchange
between different reagent flows to the inlet, two Y-valves were connected prior to the inlet port to
allow for reagent switching. Figure 5.3.2B demonstrates the glass-PDMS microfluidic device with
the naked eye. Figure 5.3.2C shows the device with all its micropillar features using a stereoscope
(image taken with a 10MP USB 2.0 Color CMOS C-Mount Microscope Camera with Reduction
Lens attached to an Amscope 7X-45X Dual Lit 6W LED Trinocular Stereo Zoom Microscope).
With the device functionally fabricated, we tested for any leakage using a syringe pump and yellow
food dye. Figure 5.3.2D demonstrates efficient flow of the food dye within the device without any
observed leakage.
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Figure 5.3.2. Microfluidic device fabrication A. Design of the PDMS-glass microfluidic in vitro
transcription device. Reaction chamber length (l): 6.6 mm, height (h): 100 µm, width (w): 600
µm. Micropillar dimensions (d): 40X50 µm, separated by gaps of (g): 20 µm. B. Picture of the
PDMS-Glass microfluidic transcription device, with mm markers above the channel for scale. C.
A closer picture of the microfluidic device taken with 10MP USB 2.0 Color CMOS C-Mount
Microscope Camera with Reduction Lens attached to an Amscope 7X-45X Dual Lit 6W LED
Trinocular Stereo Zoom Microscope. D. Picture of the yellow food dye flowing through the
microfluidic device.
5.3.3.

Packing the microfluidic device with bead-tethered transcription complex

Having demonstrated that the device was fabricated as intended, we proceeded to test the
trapping of the beads in the reaction chamber. The lateral gap between each micropillar in the array
is 20 µm, and the average bead diameter is 25 µm. With this design, we expect near complete
trapping of the beads inside the reaction chamber without leakage. Given that the beads are
magnetic, we predicted the beads could potentially stick to each other. This could cause their
clumping and clogging the inlet. We hypothesized that homogenizing the beads in a viscous
solution would prevent any possible clumping of the magnetic beads. To test the hypothesis, we
regenerated beads in T7 RNA polymerase buffer in final concentrations of 1% v/v bead and 10%
PEG-8000, as shown in Figure 5.3.3A, and flowed the solution through the microfluidic device at
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5 µL/min using a syringe pump. Figure 5.3.3B shows efficient packing of the beads in the
microfluidic device without significant clogging at the inlet, as hypothesized.

A
Homogenize
in viscous
solution

Positive Flow into
microfluidic device

B

Reaction Chamber

Bead-tethered transcription complex

Array of micropillars

Figure 5.3.3. Packing the microfluidic device with bead-tethered transcription complex A.
Bead-tethered transcription complex is homogenized in a viscous solution of 10% PEG-8000, 1%
bead v/v. B. Homogenized viscous bead solution is loaded into the reaction chamber with
positive flow using a Harvard PHD Ultra syringe pump at 5 µL/min flow rate.
5.3.4.

Microfluidic in vitro transcription using fully double stranded promoter DNA

generates encoded RNA
We next tested the system for microfluidic in vitro transcription. We packed 0.26 µL beadtethered transcription system with fully double stranded promoter DNA in T7 RNA polymerase
buffer containing 10% PEG-8000 to a final 1% v/v into the microfluidic device at 5 µL/min using
a syringe pump. After packing, we washed the system with T7 RNA polymerase buffer for 5 mins
at 5 µL/min. Transcription was then initiated with the inflow of T7 RNA polymerase buffer
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containing 0.8 mM of each NTP at 5 µL/min. We did not need to use high yield transcription buffer
and high NTP concentrations to generate high yields of RNA, since fresh NTPs are continuously
introduced to the system with the incoming flow. Similarly, we omitted pyrophosphatase as
pyrophosphate is continuously removed from the reactor.
In order to test transcription activity over time, we took fractions of products every 5
minutes. We selected the fractions taken at 5, 15, 25 and 35 mins to analyze for RNA products in
15% polyacrylamide 7M urea denaturing gel stained with SYBR™ Gold Gel Stain, as shown in
Figure 5.3.4B. The prominent bands for the 24 base encoded RNA indicate that the tethered system
is functional in the microfluidic device. Under the flow rates used, T7 RNA polymerase initiates
transcription well, without impaired promoter clearance or elongation. Aside from the encoded
RNA product, we also observed smearing of longer products. This suggests some cis primed
extension of the encoded RNA, as seen before for this construct in batch transcription reactions in
Chapter 2. In addition, we observed a sharp band, noted in the Figure 5.3.4, hypothesized to be
either prime extended RNA impurity (as seen in Chapter 2), or template DNA, judging by its
apparent length. While product profiles are similar for fractions taken before 15 min, the overall
yield drops significantly after this time point. This apparent inactivation suggests significant loss
of some component in the transcription complex under fluidic conditions, perhaps the template
DNA, which is not directly tethered in the system.

114

Strep Tactin-XT®

Magnetic Bead

A

Nontemplate

Biotin
iSp18

Te
mp
lat
e

Strep Tag II®

Strep-T7RP

B

Time (min) 5 15 25 35
Tmplt
Extended

RNA-24Alt

Figure 5.3.4. Microfluidic in vitro transcription using fully double stranded promoter DNA
generates encoded RNA. A. Bead tethered transcription complex. Strep-T7 RNA polymerase
and biotinylated fully double stranded promoter DNA are co-tethered on Strep-Tactin-XT®
beads. B. Fifteen percent denaturing 7 M urea gel stained with SYBR™ Gold Gel Stain. Fractions
taken from products fluidics in vitro transcription under 5 µL/min flow rate generating RNA24Alt using microfluidic setup shown in panel A.
5.3.5.

Tight binding promoter DNA [pss-5] retains tethered system components

under flow conditions
In the bead tethered system, template DNA is only retained by promoter affinity and by
duplex DNA contacts. In this flow application, the DNA duplex is only 44 bases in length and so
transient dissociation, perhaps facilitated by polymerase-mediated local melting(102), could lead
to continuous loss of small amounts of template DNA. On the other hand, strong promoter binding
would stabilize the complex against dissociation. In Chapter 3, I demonstrated that strengthening
promoter binding in the tethered system by using partially single stranded DNA [pss-5] allows for
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greater persistence of the complex during each washing step of the (batch) reusability experiments.
Therefore, we hypothesized that using partially single stranded promoter construct [pss-5] would
strengthen promoter affinity, and retain the entire complex tethered on beads, allowing sustained
synthesis under flow. Accordingly, we repeated the experiment demonstrated in Figure 5.3.4B
using partially single stranded DNA [pss-5]. As described in further detail in Chapter 2 and 3, this
promoter DNA has at least four times more affinity for promoter DNA, and also much lower koff
values (90–92). This stronger binding could prevent (or limit) the dissociation of template DNA
under flow conditions.
As expected, the results presented in Figure 5.3.5. show continuous RNA production, with
more retention in yield over longer times, relative to the results in Figure 5.3.4B. Thus, use of the
bead-tethered pss[-5] promoter DNA allows synthesis of RNA over at least 35 minutes, with much
improved yield of RNA over the entire time course. Moreover, the band predicted as template
DNA is not observed as prominently, suggesting it is retained better during flow, as predicted.
Alternatively, if the sharp band refers to a cis prime extended RNA impurity, using the tighter
binding promoter DNA, aids in its prevention, as previously observed in Chapter 3.
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Figure 5.3.5. Continuous RNA production without significant loss in yield using pss[-5]
promoter DNA A. Scheme of a microfluidic in vitro transcription device packed with beads cotethered with T7 RNA polymerase and promoter DNA using pss[-5] nontemplate. B. Fifteen
percent denaturing 7 M urea gel stained with SYBR™ Gold Gel Stain. Fractions taken from
products fluidics in vitro transcription under 5 µL/min flow rate generating RNA-24 using
microfluidic setup shown in panel A.
5.3.6.

Decreased flow rate allows synthesis of primer-extended RNA

The use of pss[-5] promoter DNA both increases complex stability and, as seen in Chapter
3, reduces primer extension. The primary aim of the flow approach is to further reduce primer
extension by removing product as it is synthesized. This latter effect is expected to depend on flow
rates: slower flow rates will allow the product RNA to accumulate in the chamber more than faster
flow rates. At the above flow rate of 5 µL/min, we observe some cis primed extension activity,
even for the pss[-5] construct. The model predicts that reducing the 5 µL/min flow rate to to 1
µL/min should lead to increased cis primed extension activity. Results shown in Figure 5.3.6B

117

confirm that at this lower flow rate, there is significantly more accumulation of both encoded RNA24 and 3’ self-extended longer, double stranded RNA. This result suggests that at flow rates of 1
µL/min, RNA is not removed from the reaction chamber fast enough to prevent its accumulation
and rebinding by T7 RNA polymerase. Using higher flow rates resulted in an overall loss of
transcription (results now shown), predicted as a result of washing off of a system component.

A

Reactor
RNA, PPi

(NTPs, Mg(II)

Magnetic Bead

NTPs, Mg(II)
Nontemplate

Biotin
iSp18

Te
mp
lat
e

1 µL/min
15

25

35

45 55 Time (min)

5 µL/min

5

15

25

35

Time (min)

Extended

5

C

Extended

B

Strep Tactin-XT®

RNA-24

RNA-24

Figure 5.3.6. Increasing flow rate reduces RNA accumulation in reaction chamber, preventing
RNA 3’ self-extension A. Scheme of a microfluidic in vitro transcription device and tethered
transcription system with pss[-5] nontemplate. B. Fifteen percent denaturing 7 M urea gel
stained with SYBR™ Gold Gel Stain. Fractions taken from products fluidics in vitro transcription
under 1 µL/min flow rate generating RNA-24 using microfluidic setup shown in panel A. C.
Fifteen percent denaturing urea gel stained with SYBR™ Gold Gel Stain Fractions taken from
products fluidics in vitro transcription under 5 µL/min flow rate generating RNA-24 using
microfluidic setup shown in panel A.
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5.3.7.

Comparison of batch and flow synthesis

Finally, we compared the product profiles of the fluidic in vitro transcription reaction with
low and high yield batch in vitro transcription reactions. For low and high yield batch in vitro
transcription batch reactions, we used untethered, partially single stranded promoter DNA [pss-5],
and T7 RNA polymerase at 0.8 µM final concentrations. Fluidic in vitro transcription reaction was
carried under the same conditions as in Figure 5.3.5. In the comparisons presented in Figure 5.3.7,
the batch 5 min in vitro transcription reaction was initiated with T7 RNA polymerase buffer and
0.8 mM NTPs while the batch 1 h in vitro transcription reaction was initiated with high yield
transcription buffer and 7.5 mM NTPs. The batch 1 h in vitro transcription reaction was diluted
20-fold (note the reduction in the template DNA band) to compare yields with the batch 5 min in
vitro transcription and the results reveal similar product profiles. It is important to note that, as
demonstrated earlier in Chapter 2, using partially single stranded promoter DNA [pss-5] as
opposed to [pss+2] prevents the RNA rebinding and extension activities even without added salt.
For this reason, the overall improvement of encoded RNA production with fluidic in vitro
transcription is not as significant here as it was in methodologies demonstrated Chapters 2 and 3.
In batch transcription product lanes, there are two sharp bands where 24 base RNA would run,
indicating the prominent production of RNA-24, with slower migrating products at lower
intensities, suggesting some primer extension. These profiles are quite similar to the ones we
observed in low salt transcription in Chapter 2, where we used pss[-5] to drive T7 RNA polymerase
affinity to promoter. The two sharp bands and the longer smear are highly identical to that profile,
as expected.
Under flow conditions, sampling at 5 min, the higher of the two sharp bands is not
generated as much and therefore the lower band (suggested 24 nt encoded RNA product) has an
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increase in yield when compared with batch products. While the yield of encoded-length RNA is
the highest under these conditions, there are still some extended products observed (we also see a
small release of template DNA, as previously observed at 5 µL/min flow rates). Future studies will
tune the flow rates to optimize purity and yield.

Batch Flow
5m 1H 5m

Extended

Tmplt

RNA-24

Figure 5.3.7 Comparison of Batch and Flow Transcription Profiles and Yield. Transcription
product RNA-24 from 5 min and 1 h batch reactions and a flow reaction sampled at 5 min are
shown. Batch 1 h was diluted 20-fold to allow for purity comparisons with the batch and flow 5
min product yields. Products were analyzed by 15% acrylamide, 7M urea denaturing gel
electrophoresis, and detected via SYBR™ Gold gel staining.
5.4 DISCUSSION
In Chapter 3, we established a novel methodology that generates high yields of only
encoded RNA without the double stranded impurities—reducing the need for extensive
purification post synthesis. Now that RNA therapeutics is in the forefront of medicinal
breakthrough, we need to further improve methodologies for automated mass production of highly
pure RNA.
In this Chapter, we establish a novel, automated microfluidic in vitro transcription device to
generate high yields of pure RNA without the longer, double-stranded impurities. In this approach,
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bead-tethered transcription complex (established in Chapter 3) is contained inside the reaction
chamber of a microfluidic device designed for this study. Transcription starts with the inflow of
transcription reagents into the reaction chamber. Encoded RNA is generated and simultaneously
removed from the reaction chamber with continuous flow, while the bead-tethered transcription
complex is contained within the reaction chamber. As a result, RNA accumulation near the
polymerase is limited, and so is the generation of longer, double stranded RNA impurities.
5.4.1

A novel microfluidic in vitro transcription device

The images shown in Figure 5.3.2 of the microfluidic device designed in Figure 5.3.1
illustrate that this design can be easily manufactured using standard soft lithography techniques.
We optimized the system to efficiently deliver the beads into the reaction chamber by first
homogenizing them in a buffer containing 10% PEG-8000 to prevent their clogging in the device
inlet. We successfully packed about a calculated volume of 0.26 µL beads in the reaction chamber,
as shown in Figure 5.3.3. While bead-blocking micropillars retain the beads, lateral spacing
between micropillars allows for unrestricted flow of solution.
Results in Figures 5.3.4 and 5.3.5 clearly demonstrate efficient on-bead synthesis under
flow conditions. It is interesting to note that with a reactor volume of about 0.4 µL (packed with
an approximate amount of 0.26 µL beads) and a flow rate of 5 µL per min, the reactor undergoes
a complete exchange of buffer about 12.5 times per minute. In 4 minutes, a total of 20 µL would
get introduced into the system, equaling to the total NTP amount a 20 µL low yield batch reaction
would use. This compares nicely with the overall yield of 5 min batch and flow products
demonstrated in Figure 5.3.7. The overall yields of transcription are similar between the flow and
5 min batch reactions. It is important to note that the flow conditions generate more of the 24 nt
encoded RNA when compared with the batch 5 min. This is due to the prevention of RNA
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accumulation in solution. Similarly, 1 hr batch reaction produces a similar profile of RNA products
as the 5 min batch. We can conclude that flow reaction generates RNA with superior purity when
compared with batch reactions.
5.4.2

Strengthening promoter contacts using pss[-5] helps retain template DNA on

beads, allows for longer transcription runs
To a first approximation, since polymerase and the nontemplate strand of the DNA should
be tightly bound to the beads, transcription should occur indefinitely. However, since this is a flow
system, even transient dissociation of one component of the reactor will slowly lead to depletion
of that component in the chamber. The cartoon in Figure 5.3.1C illustrates four main forces holding
the reactor complex together: 1) biotin-Strep Tactin-XT® interaction, 2) Strep Tag II®- Strep
Tactin-XT® interaction, 3) DNA:DNA duplex, 4) promoter DNA-polymerase interaction. These
main forces together ensure tight binding of the complex together (note that the template strand is
tethered only indirectly to the beads). In Figure 5.3.4B, denaturing gel front shows the products
from the fluidic in vitro transcription where a bead-tethered system with fully double stranded
promoter DNA was employed. The data presented in Figure 5.3.4B clearly demonstrate that RNA
is efficiently synthesized on the beads under continuous flow using a bead-tethered system with
fully double stranded promoter DNA. From the size markers, we are able to see product RNA,
extended double-stranded RNA impurities, and a longer sharp band size of the template DNA (that
could be both longer RNA impurities or washed off template DNA). In an ideal reactor, synthesis
would be continuous for extended periods, allowing for high total yields of RNA per enzymeDNA complex, much higher than could be achieved in a conventional batch reactor. While
transcription is continuous for 15 min, by 35 min, the yield of RNA decreases significantly using
a bead-tethered system with fully double stranded promoter DNA.
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It is well known that the pss[-5] construct binds RNA polymerase with about ten-fold
stronger affinity than the fully double stranded promoter DNA (93, 103). More importantly, it
shows a substantially reduced dissociation kinetic rate constant. Thus, we expect the promoter
bound complex to be more resistant to flow(90–93, 103). As expected, the transcription with the
immobilized pss[-5] construct shown in Figure 5.3.5 demonstrates notably longer transcription
runs.
The use of this construct provides an additional benefit clearly visible in Figure 5.3.5. As
initiation is mostly a kinetic event, the reduced kinetic dissociation rate of pss[-5] promoter DNA
directly correlates to the strengthening of promoter binding. This helps initiation to compete better
with the rebinding of RNA to drive primer extension, yielding a higher ratio of encoded 24mer to
longer primer extension products.
5.4.3

Increased flow rate prevents RNA accumulation near T7 RNA polymerase

eliminating its cis primed extension activity
In either of the above scenarios, faster flow rates will carry away any transiently dissociated
reactor components. Thus, although the promoter contacts were strengthened by using the pss[-5]
construct, overall transcription is clearly decreasing at 35 minutes (longer times were not tested).
This suggests that at 5 µL/min flow rate, some template DNA could be lost under flow despite
using pss[-5] to strengthen its promoter contacts.
In order to reduce the depletion of the fully assembled reactor, we next reduced the flow
rate from 5 to 1 µL/min. The results shown in Figure 5.3.6 show that at this lower flow rate,
transcription continues at a good rate out to at least 55 min. However, the extended transcription
occurs at a cost of overall purity. This is expected, since the lower flow rates allow RNA
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concentrations within the reaction chamber to rise to higher levels, driving product rebinding to
the polymerase.
While continuous flow should remove encoded RNA from near polymerase that generated
it, it is important to note that the 6.6 mm long reaction chamber is packed with 0.26 µL of beads
along the channel. It is reasonable to predict that tethered complexes upstream of the reactor bed
(closer to inlet) generate primarily encoded RNA. Farther along the reactor bed, at 1 µL/min flow,
RNA products accumulate both from local synthesis and from upstream synthesis, such that RNA
accumulating closer to the outlet can rebind the polymerase to generate primer extended products,
resulting in longer impurities.
The results in this Chapter clearly demonstrate the continuous synthesis of encoded RNA
in a flow reactor. At sufficiently high flow rates, RNA should not accumulate substantially,
yielding both higher purity and higher overall yield of the encoded RNA. However, lower flow
rates may more efficiently consume substrate NTPs. In order to compensate for lower flow rates,
RNA rebinding could be inhibited by adding salt in the buffer, as described in Chapters 2 and 3.
With

co-localized

tethering

of

pss[-5]

A

B

promoter DNA (for its strong promoter
affinity) and RNA polymerase we predict that
the reactor could be run at elevated salt
concentrations, as demonstrated in Chapters 2
and 3. Since transcription under 1 µL/min
flow rate seems to be generating more RNA
overall at longer times without significant loss
in overall yield, at this point, an end user can

Figure 5.3.8. Potential next generation
parallel reactor configuration. A) current
design; B) parallel reactors allow for shorter
reactor beds, but with the same overall
capacity.
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adjust the flow rate to balance the need for yield versus purity. A good tradeoff would be using a
slow flow rate such as 1µL/min and combining it with a transcription buffer with ~0.2-03 M added
NaCl, as demonstrated to be an effective implementation in producing clean RNA, discussed in
further detail in Chapter 3.
If under such conditions, there is still significant loss in yield due to washing of system
components, future researchers may choose to use recently developed Strep-Tactin®XT
Superflow® high-capacity resin, as it can be used under low pressure flow conditions.
Alternatively, next generation devices may incorporate shorter reactor beds in parallel (i.e., multichannel or stacked devices for high yield output (104, 105), as illustrated in Figure 5.3.8.
5.4.4

Device produces comparable RNA yield to high yield batch in vitro

transcription reactions
The experiments shown in Figure 5.3.7 compare product profiles of batch and flow in vitro
transcription reactions. Flow in vitro transcription at a 5 µL/min flow rate generated significantly
more encoded RNA when compared with batch reactions and low and high yield conditions
without loss in overall yield. When comparing the yields between the 1 hr batch and flow products,
we can compare the NTPs used by high yield batch and flow systems to conclude an estimate of
overall time needed to generate the same amount of RNA. 1 hr batch reactions use 7.5 mM of each
NTPs. For the flow system to get introduced with this much NTPs, the system would need to get
187.5 µL of 0.8 mM NTPs introduced. Since the rate of flow is 5 µL per min, this would equal to
a total time of 37.5 minutes. That said, if the transcription rate is similar between both systems, in
37.5 minutes, the flow system would expectedly generate the same amount of RNA that high yield
batch transcription would generate under longer times (i.e., 4 hours). This is clearly a benefit when
considering the time cost of high yield batch transcription reactions.
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Given that flow is productive for 35 minutes and uses ~9.4 times less NTP per volume, if
flow reactor was introduced with a total of 187.5 µL NTPs in 37.5 minutes, it would expectedly
generate the same RNA spread out over ~9.4x volume. The time savings of the flow is obvious
here. If the influx of transcription reagents continued, flow would generate ~6.5 times RNA in 4
hours when compared with the high yield batch reactions. The time savings and yield increase of
the flow device then, is superior by a significant multiple.
5.5 SUMMARY
In summary, we have developed a simple RNA microfactory where synthesized RNA is
removed from bead tethered T7 RNA polymerase and promoter DNA shortly after synthesis,
preventing RNA rebinding and cis-primed extension activities that otherwise would produce high
yields of longer, double stranded impurities.

126

DNA sequences and constructs used in Chapter 5

A

5'-AATTAATACGACTCAC-3'

NT- pss[-5]

5'-5BiosG/iSp18/TTTTTAATTAATACGACTCACTATAGGAGGTACTACGTCGACGCATTTA-3' NT-Biotin 24Alt

B

Template Strands

5'-5BiosG/iSp18/TTTTTAATTAATACGACTCAC-3'

24 3’-TTAATTATGCTGAGTGATATCCTCCATCATCTCCACTTCTAAAT-5’
24Alt 3’-TTAATTATGCTGAGTGATATCCTCCATGATGCAGCTGCGTAAAT-5’

5BiosG
5’ Biotin with standard
C6 linkage

iSp18
18-atom hexa-ethyleneglycol spacer

*Consensus promoter sequence shown between dashed lines
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NT-Biotin pss[-5]

Nontemplate
Strands

Table A4.

CHAPTER 6
CONCLUSIONS & FUTURE DIRECTION
RNA therapeutics have advanced significantly over the past decades and are slowly
replacing conventional drugs (small molecules and protein replacement therapies), as discussed in
detail in Chapter 1. The number of FDA approved RNA therapeutic therapies is increasing each
year (106), with the most recent emergency approval coming to mRNA-based vaccines by
BioNtech/Pfizer and Moderna (107, 108). Although the global pandemic is an especially daunting
period globally, it has come at a time that has allowed the mRNA therapeutics approach to step up
significantly to offer relief. This fast of an advancement was not expected, but it was made possible
as researchers and companies exploited decades of research and knowledge to rise to the challenge.
When compared with conventional medicine, two key advantages of RNA therapeutics are
1) development speed and 2) application versatility. The superiority of RNA therapeutics
development speed was clearly demonstrated in 2020, as two pioneering examples of mRNAbased vaccines were developed in record time by parallel groups at BioNtech/Pfizer and
Moderna/NIH to provide relief against the global Covid-19 pandemic (16, 109, 110). Moderna
developed and initiated clinical trials of mRNA-1273 only 6 weeks from the publication of the
genome sequence of SARS-CoV-2; a breakthrough accomplishment in record time in medicinal
history (16, 111). Traditional vaccines have taken decades to develop, and this breakthrough
timeline of mRNA vaccine development exemplifies the promise of RNA therapeutics in relieving
other likely future global pandemics. The second most important advantage of RNA therapeutics
is versatility, and this advantage can be demonstrated with an example. As viruses mutate,
traditional vaccines developed for the original strain often fail to immunize against the mutated
strain. Thus, in traditional vaccines, researchers need to commit to a new research and development
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process to be able to establish a novel vaccine for the mutated strain. Whereas with mRNA
vaccines, a completely novel vaccine need not be developed. If an mRNA-vaccine is already
established for a target virus strain, it can be adapted to any mutated version just by changing the
ORF region of the mRNA used in the vaccine. As soon as the genome sequence of the mutated
strain is decoded, it could take only a week to develop the novel vaccine for the mutated strain.
These two areas (speed and versatility) exemplify the most important advantages of RNA
therapeutics and demonstrate how it holds the power to digitize and transform conventional
medicine (112).
Currently, RNA therapeutics is at the forefront of global attention due to the mRNA
vaccine efforts. This field has advanced significantly over the past decades and is poised to rapidly
compete with conventional drugs (i.e., biologics and small molecule drugs) for various treatments
and vaccines due to the numerous advantages it offers (3, 113). It is poised to transform medicine
to a versatile, digitized and more customizable position, and accordingly is expected to gain even
more momentum in the years to come. As such, it is evident that high yields of pure RNA will be
needed in the upcoming decades to support the rapid advancement of novel RNA therapies.
All mRNAs and many other small RNAs are synthesized in vitro by T7 RNA polymerase
under high yield conditions (18, 20, 23, 66). While chemical synthesis is able to generate high
quality RNAs of up to only about 50-100 nt (with low yields and purity at the higher lengths),
enzymatic synthesis using T7 RNA polymerase can generate high yields of RNA of all lengths.
While this enzyme is highly promoter specific and robust, it is also known to participate in
significant non-promoter driven activities (20, 25, 30–32, 34, 36–46). Our lab recently
demonstrated that T7 RNA polymerase generates RNAs longer than the encoded length, through
a cis primed extension mechanism (32). When high yields of RNA accumulate in solution,

129

polymerase binds the 3’ end of RNA and extends the RNA using the RNA as a self-template,
resulting in a heterogeneous and distributive pool of double stranded, longer than encoded RNA
impurities (20, 28).
While researchers follow up in vitro T7 RNA polymerase transcription with extensive
purification methods, along the process, they sacrifice quality and yield of the encoded RNA
recovered (60–65). Plus, current purification methods cannot fully recover only the encoded RNA
from a heterogeneous pool. For example, an mRNA of 3000 nt cannot be easily purified from a
double stranded RNA impurity of 3050 nt RNA. Past reports noted that in vitro transcribed RNA
can induce the innate immune response in therapeutics applications (62, 69, 114). This is likely
due to the dsRNA impurities that were generated through cis primed extension and could not get
purified with standard methods used. Especially in RNA therapeutics applications, without
complete elimination of double stranded RNA, these impurities may activate the potentially lethal
immune response. All in all, it is evident that the inventions in this dissertation can help in three
major areas: 1) encoded RNA yield & scalability for the industry 2) encoded RNA purity 3)
preventing the innate immune response in therapeutics applications.
In Chapter 1, I described the significance and future of RNA therapies and vaccines, the
current methods used to generate and purify high yields of encoded RNA, the origin of enzymatic
transcription impurities in high yield reactions, and the problem with the double stranded nature
of such impurities. This depicted a clear understanding of why there is an urgent need to update a
more than 30-year-old enzymatic RNA generation protocol. In chapter, I will briefly summarize
the technologies invented in Chapters 2-5 and elaborate on how each technology might be
beneficial to different end users. I will conclude with future directions on each technology and
how they might be integrated to various downstream applications.
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In Chapter 2, we established a novel in vitro transcription method that inhibits product
RNA binding, while fully retaining promoter transcription. In previous years, multiple labs
demonstrated that partially single stranded promoter DNA (pss[-5]) binds T7 RNA polymerase
more tightly. In this research, we used partially single stranded promoter DNA (pss[-5]) to
strengthen promoter binding (90–92). To further eliminate the cis primed extension activity of the
enzyme, we increased added salt concentration. Using pss[–5] drives initiation of transcription to
better compete with cis primed extension, and increasing added salt further inhibits any RNA
rebinding activity. Transcription is resistant to salt, and the method is universal to other sequences
and lengths. While we only tested the method for RNA shorter than 40 nt, we expect it to be
functional for longer RNA due to its observed ability for efficient promoter clearance. The strong
promoter binding may impair the transition to elongation, but not at a rate that is detrimental. The
apparent side product of this impairment is a 12-15 nt RNA, which can be easily separated from
encoded RNA by routine purification methods. This method is relatively straightforward and lowcost. Researchers who aim to generate short RNA and use synthetic DNA constructs can order the
short nontemplate strand and couple it with their desired template DNA. Using high yield
transcription buffer recipe optimized in Chapter 2 with 0.3-0.4 M added salt, they can improve
both the purity and yield of the product RNA. We expect this method to be of great use to small
labs in academia, and other labs in industry that routinely generate short RNA such as gRNA for
CRISPR applications. The straightforward nature of the protocol makes it easy to implement,
without further need to optimize conditions.
In Chapter 3, we established another novel in vitro transcription method based on a
fundamentally similar idea as that described in Chapter 2, but one that is functionally different.
Transcription is carried out under high salt to eliminate RNA product rebinding, while promoter
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DNA and T7 RNA polymerase are co-tethered in proximity on magnetic beads to drive promoter
binding and initiation. This combination results in an increase in overall yield and purity of the
encoded RNA. The tethered system favors promoter-directed transcription at high salt; but does
not impair promoter clearance or elongation, unlike the method used in Chapter 2. While pss[-5]
impairs promoter clearance, as demonstrated previously by our lab (73), tethering does not seem
to have such effect by itself or with combination of added salt. The tethered system was shown to
be applicable for RNA of different sequences and lengths (tested up to 40 nt in this research).
This new system also offers dramatic improvements in encoded RNA yield and purity.
Transcription can be repeated in batch syntheses by reusing the tethered system without significant
loss in yield between repeats. Whilst developing the system, we found that using pss[+2], a mimic
for full length dsDNA templates, leads to loss in overall yield in batch repeats. However,
strengthening promoter contacts by using a pss[-5] promoter DNA leads to longer retention of
usability in each round. Using pss[-5], the tethered system was demonstrated to be reusable over
at least three rounds of batch transcription (the maximum attempted to date) without any
significant loss in overall encoded RNA yield.
Transcription with both components tethered to a solid support sets the stage for
microfluidic reactors described in Chapter 5, but also can be used in its own right to improve
throughput. Previous batch reactors developed by Tesla and Davis only tether DNA to the solid
support(57, 59). Accordingly, these batch repeat systems require addition of fresh enzyme every
round of transcription. Our system allows both DNA and T7 RNA polymerase to be reused
multiple rounds. This will be important for cost savings in RNA production. Furthermore, those
batch systems demonstrated by Tesla and Davis allow high yields of product RNA to accumulate
near T7 RNA polymerase. As demonstrated previously, accumulation of RNA near polymerase
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exacerbates cis primed extension and result in the generation of double stranded RNA impurities.
Our system is designed to prevent the polymerase from interacting with the product RNA, ensuring
only promoter driven transcription to take place in solution. Therefore, our system is superior in
terms of the purity of the RNA produced as well.
In Chapter 4, we developed a novel affinity capture method for the purification of in vitro
transcribed RNA in high yields. We first demonstrated that immobilized DNA complementary to
the 3’ end of the RNA can be used to selectively purify only the desired RNA from a pool of
heterogeneous products, post transcription. Next, we improved a previously demonstrated
methodology from our lab(47) where RNA self-primed extension is competitively inhibited using
a similar 3’-complementary capture DNA oligo in the transcription reaction. In a new application
we employed a biotinylated capture DNA and followed transcription by mixing the crude
transcription reaction with streptavidin beads. While the method was successful fundamentally,
the low capacity of the magnetic streptavidin beads posed a challenge in applying the method to
high yield product pools. For this reason, we tested the approach with high capacity Strep-Tactin®
XT beads and demonstrated its ability to affinity capture high yields of product RNA in solution.
While this study was not completed, it was shown that these beads can capture high yields of in
vitro transcribed RNA in solution. We expect with minor optimizations along the protocol, results
of this project can be realized in short time.
I also developed a novel purification technology to improve the capacity of any bead used
for affinity purification of in vitro transcribed RNA. In this novel invention, the capture capacity
is improved by using rolling circle amplification to generate a single longer DNA containing
multiple capture sites. While the bead binds the same molar amount of DNA, a single DNA can
capture many product RNAs, amplifying the bead capacity. Whilst optimizing the protocol, we
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realized that adjusting the rolling circle amplification time and conditions were crucial. Further
optimizations are required in order to prevent tangling of the long DNA, while ensuring long DNA
production for the purification of high yield of RNA. This project can also be integrated into the
microfluidic chip developed in Chapter 5, in a downstream chamber, to capture only desired RNA
and purify it in the solution of choice, free of Mg, NTPs and other biproducts of transcription. We
expect this approach to decrease the need to follow lengthy and laborious purification steps
implemented by current researchers in the field.
Finally, we developed a novel universal capture DNA purification system where a
universal DNA oligo with a fixed sequence is immobilized on beads, a dual capture DNA oligo
with complementarity both to the universal DNA oligo and to the 3’ end of the RNA to be purified
binds to the universal DNA oligo, and product RNA can be recovered efficiently from a
heterogeneous pool of products. While this system had roadblocks in its use during synthesis, we
suggest its most appropriate use to be for purification on any RNA sequence after transcription. It
can be combined with the microfluidic chip in Chapter 5, in a manner similar to the one I
mentioned in the previous paragraph.
The purification methods elaborated in Chapter 4 have the potential to rapidly achieve
purities that are currently attainable only through lower efficiency and more labor intensive
chromatographic (or gel electrophoretic) approaches. Importantly, while the latter become more
difficult with increasing length of the RNA, this approach should be relatively independent of
RNA length. We expect this to be of great importance to all labs where double stranded RNA
impurities may not be easily purified with generic purification methods, where researchers look
for a cleaner RNA to be used for downstream applications. This might be of great importance for
nanotechnology (i.e., DNA origami, toehold reactions) and for therapeutics applications. Its
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combination with a microfluidic system would offer the possibility of a “one-push” closed
system/devide for transcription and purification of any desired RNA.
In Chapter 5, we established a novel fluidic in vitro transcription device where the tethered
DNA-enzyme system developed in Chapter 3 is trapped inside a flow reaction chamber. As
substrate flows into the reactor, encoded product RNA is continuously flowed away from the
reaction chamber and collected in an Eppendorf tube. We successfully demonstrated fluidic in
vitro transcription of encoded RNA using the pss[+2] promoter construct. Flow conditions did not
seem to negatively impact the initiation and elongation events, allowing full transcription
functionality of the trapped tethered system, as expected. However, as in the repeat batch reactions
with the pss[+2] promoter construct, we observed an overall loss in transcription after 15 minutes.
To overcome this issue, we used the pss[-5] promoter construct, which binds polymerase more
tightly. With that, we retained transcription of the encoded RNA for about 35 minutes of run time.
To further improve the retention of the template DNA, we tested a lower flow rate and observed
continuous transcription for 1 hr. Slower flow rates resulted in the product RNA accumulation
near enzyme and resulted in increased rate of primer extended RNA products, as expected by the
model. Future applications of this approach can adjust flow rate to balance yield vs purity. To
further improve purity at lower flow rates, researchers can include added salt in the transcription
buffer, as previously demonstrated to provide relief in Chapter 3.
While repeat batch reactors have been previously described, this is the first in vitro
transcription in a microfluidic (lab-on-a-chip) system. There are two other systems that targeted to
automate the transcription system in literature, as demonstrated by Davis and Curevac/Tesla (57,
59). Those systems are not considered fluidic setups; they are repeat batch reactors that aim to
reuse the DNA component to save on cost. The limitations of these automated systems are in their
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batch nature. In their batch reactors, they require introduction of fresh RNA polymerase with each
batch, losing the opportunity to save on cost on reusing the enzyme. More importantly, these batch
reactors do not alleviate the critical setback of conventional high yield in vitro RNA transcription
protocols- which is the accumulation of product RNA near T7 RNA polymerase. It is known that
as product RNA accumulates in a batch reactor near RNA polymerase, the enzyme (through mass
action) binds 3’ end of product RNA, and self-extends through a cis primed extension mechanismresulting in significant yield of dsRNA impurities (31, 32). In contrast, our system 1) automates
the manufacturing process, 2) allows all transcription components (promoter DNA and T7 RNA
polymerase) to be reused, and 3) prevents any accumulation of RNA near polymerase, preventing
the formation of dsRNA impurities. Initial estimations in Chapter 5 further suggest savings on
time, as a 30 min flow reaction and a 4 hr traditional high yield batch reaction is estimated to
generate similar RNA yields. We expect our platform to be invaluable for RNA manufacturing
needs, where time and cost considerations are paramount, and purity is essential to success of any
downstream need.
The philosophy of our microfluidic transcription system resembles the lean production
system originally implemented in Toyota car manufacturing facilities, pioneered by Taiichi Ono
(115). While the main production philosophy of Ford manufacturing system was producing large
quantities to save on cost, Toyota system revolutionized the approach by focusing on reducing
overproduction and inventory management (115). They focus on eliminating waste and non-valueadded activities, and improving the overall quality of the produced item (115). While those systems
were established for the manufacturing needs of the automotive industry, it is not difficult to apply
these ideas to biotech (116).
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In our research, by favoring promoter-driven transcription over non-promoter driven
activities, we essentially eliminate wasteful production of longer, double-stranded RNA
impurities. The revolutionary change LPS brought to car manufacturing and other fields is clearly
demonstrated in its countless methods of implementation on production systems and management
practices (117–119). This year, we witnessed another revolutionary manufacturing system led by
a U.K based electric vehicle company called Arrival. In a novel approach, manufacturing is
focused on small scale, distributed production facilities. The flexibility of their system offers the
ability to setup tandem manufacturing cells that can be added and discarded as the need arises.
This gives the opportunity to control production scale and offers the opportunity for facile
customization. It also offers significant cost-savings in manufacturing, inventory management and
production facility real estate. Most importantly, it leaves ample room for real time innovation, as
novel components can be added to a production setup, simply with the addition of a novel cell to
the distributed manufacturing process.
These manufacturing pivot points in large automotive production systems can be used as
an informative booklet to set up the stage for mass manufacturing of RNA and innovating novel
RNA therapeutics in an automated, customizable, and highly digitized approach. The main benefits
of RNA based therapies are digitization and customization of medicine. Accordingly, such
manufacturing and drug development processes are paramount in this field’s continued success in
the long term. To give an example for a future possibility, we can brainstorm what manufacturing
and development arenas are possible, based on the new platforms we establish in this dissertation.
It is important to note that the scope of lean RNA manufacturing platforms we establish in this
thesis does not need to be limited for in vitro transcription. It can be used as a baseline to satisfy
automated, efficient and scalable manufacturing needs in RNA therapies as a whole. It can also be
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used in expanding the possibility of how next generation inventions are developed. In this new
way of thinking, it is possible to say that lean manufacturing and automation can inform the
scientific teams in the innovation needs, and both sectors can work hand-in-hand, constantly
talking to each other and improving with information gathered at both sections. This will be the
new age of innovation, where innovation is not only conceived by scientists in lab, but a new
direction where continuous improvement strategies are conceived collaboratively with research
and development, manufacturing and management teams. The future possibilities of what is
established in this dissertation then, are three tiered: manufacturing, distributed production
(improved distribution) and novel therapy development.
First, in its manufacturing capability, high yields of RNA can be produced in a systematic,
controlled, scalable and highly reproducible fashion. The microfluidic device can be connected to
other downstream microfluidic or fluidic setups. For instance, in the case of producing an mRNA
vaccine, the manufacturing facilities rely heavily on manual handling that require highly trained
technical staff. They also need to adhere to strict Good Manufacturing Practices (GMP) regulations
(112, 120). As a result, current manufacturing processes are costly, laborious, time consuming and
take up significant space in house manufacturing facilities. Many DNA templates to be used for
mRNA production are generated in house, starting with the preparation of plasmid DNA, followed
up with transcription, purification, 5’ and 3’ capping, and encapsulation in optimized delivery
vehicles (112). Our microfactory platform offers an opportunity to automate this entire process in
massively parallel, tandem microfluidic devices. For instance, in this research, we demonstrated a
continuous flow system for the high yield generation of encoded RNA without the double stranded
impurities. In an alternative system, our setup could be used to develop an automated system for
the incorporation of modified bases selectively or throughout the RNA. With the prevention of
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dsRNA generation, there should not be a need for incorporating synthetic nucleotides (e.g., pseudo
(ψ)-UTP), but if needed the system would be fully compatible with the use of such modified bases.
For mRNA vaccines, 5’ and 3’ capping could be implemented post transcription downstream the
flow transcription within a tandem microfluidic chip, or cotranscriptionally within the setup
developed here. Furthermore, the platform can be combined with other downstream microfluidic
devices to prepare the RNA for vaccines or therapies in the optimized delivery vehicle of choice.
This way, from transcription of RNA to final drug preparation in the desired delivery format, all
processes can be combined in an automated, microfluidic setup in a cheap and versatile manner.
This would offer enormous flexibility on what can be produced in a microfactory. A new microchip
could be developed separately, and added in tandem to the production line, when needed to further
customize the produced RNA or therapy for customer’s need.
The core idea here is a distributed microfactory approach where series of tandem
microdevices can be brought to different production sites (i.e., clinics) and only the desired product
at required yields can be produced with superior purity and quality. This, in its essence is similar
to the core idea of the LPS system, as no production is unintended, and only what is desired is
produced with excellent quality. If we add in the flexibility of distributed manufacturing ideology
implemented by Arrival EV for car manufacturing, we can envision an ultimately superior drug
manufacturing platform for the RNA therapeutics industry. All in all, the microfluidic automated
system would streamline manufacturing processes and allow for its use at any hospital/company
set up in a facility of choice. The enclosed fluid path, scalable production system, automated use
and flexible addition/separation of tandem components are all attractive points to lower labor and
manufacturing cost from a supplies chain standpoint. This platform can decrease the need for
manual intervention, and set up the stage for a streamlined, automated manufacturing setup.
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Second, following the example of the generation and distribution of an mRNA vaccine,
there remains the challenge to distribute the vaccine to the world at large. With the generic
production systems used, companies make abundant products at home manufacturing facilities and
distribute them to partner facilities throughout the world, within temperature-controlled systems.
Such systems add up to the cost and pose novel constraints in the supply chain, such as the
requirement for dry ice and storage containers, the reliability of shipping and delivery (112). The
idea of an automated tandem microfluidic set up that can generate an mRNA vaccine from
transcription to encapsulation within an optimized delivery path, then, is one that can alleviate
these steps. With a streamlined microfluidic setup, such a microfluidic setup could be distributed
to the world for production of vaccines at the delivery site, according to the need. This further
supports the idea of a lean manufacturing system where only the required amount of RNA is
produced for the required need of vaccines at the location of manufacturing.
Third, from a novel therapy development lens, our platform sets the stage for its ability to
offer the production of a vast number of therapeutic leads to be tested. In tandem chips, different
RNAs can be generated, and combined with a number of delivery vehicles, creating a library of
therapy candidates. It would make the lead selection process streamlined, automated and with the
abundant selection catalog would set the stage for developing a successful RNA therapy. Since
RNA therapeutics can be applied for a vast number of diseases, the factories then offer the
possibility to enhance this field and bring novel therapies to clinic in short time. Only with such a
production and development system, RNA therapeutics field can reach the digitized, versatile and
customizable feature envisioned.
The global pandemic has pushed the RNA therapeutics industry to step up significantly.
We are now in a place to apply decades of knowledge to bring RNA therapeutics into the clinic.
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With this new era, it is not sufficient to generate some quantities of RNA in lab, follow up with
extensive purification protocols and prepare for their drug delivery vessel in separate workstations.
We are now at a place where high yields of RNA are needed to be manufactured at large quantities
in an automated and streamlined manner. We expect our novel RNA microfactory platform to
disrupt the current RNA manufacturing processes and set the stage for novel therapy development
strategies. The future of digitized and customizable RNA therapeutics is here and can be exploited
if we can make the most the automated, clean manufacturing approaches developed in this
dissertation and use our system to develop massively parallel microfluidic RNA production and
therapy development setups.
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